Uses of sesquiterpene lactone compounds and their derivatives in drugs preparation

ABSTRACT

The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of Formula (I) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.

BACKGROUND OF THE INVENTION

Technical Field

The present invention belongs to the field of drug technology, specifically relates to the uses of sesquiterpene lactone compounds as the effective components or pharmaceutical composition in preparing drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.

Description of Related Art

The rheumatoid arthritis (RA) is a chronic, inflammatory and systematic autoimmune disease. In addition, the tumors greatly threat the health of human. There are approximately two million of cancer patients in China currently and 1.6 million of cases are emerging every year, which is a rather huge number. RA is a progressive and multi-joint inflammatory systemic autoimmune disease, which mainly shows inflammatory hyperplasia of synovium, mononuclear cell infiltration and neovascularization. There is no therapeutic solution and preventive measures for radical cure of these diseases yet and the main drugs prescribed clinically include non-steroidal anti-inflammatory drugs and adrenal cortical hormones, etc. However, these drugs have severe side effects to result in damages to liver and kidney as well as pulmonary fibrosis. Therefore, it is difficult for the patients to adhere to long-term medication. Thus, our purpose is to find an effective and safe medicine for the treatment.

So far, there is no report concerning the application of the compounds of Formula (I) and their pharmaceutical compositions in preparing drugs to cure rheumatoid arthritis.

The tumors greatly threat the health of human. There are approximately two million of cancer patients in China currently and 1.6 million of cases are emerging every year, which is a rather huge number. Therefore, the anti-tumor research is a very challenging field, but with great significance to the present life science. The therapeutic methods in the past focus on eradicating and killing cancer cells and the anti-tumor drugs often used clinically are mainly cytotoxic agents so far. However, these anti-cancer drugs have the demerits such as poor selectivity, strong toxic side effects and tending to result in drug resistance, so they are typical double-sided drugs and it is difficult with them to eradicate cancer and a high ratio of some cancers tend to recur. High recurrence rate of malignant tumors is always a challenge annoying the oncologists. More and more studies have demonstrated that there are a small number of tumor stem cells in the tumor cell population, which can amplify the population. They are usually at the slow cycle state with low sensitivity to chemotherapy drugs and are the origins of tumor recurrence. Thus, the discovery of tumor stem cell provides a new target for tumor treatment and the drug research against tumor stem cell provides the possibility to completely heal cancer.

So far, there is no report concerning the application of the compounds of Formula (I) and their pharmaceutical compositions in treating cancer through inhibiting cancer stem cells.

BRIEF SUMMARY OF THE INVENTION

The present invention provides the uses of the compounds of Formula (I) in preparing drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells.

where: R₁ and R₂ form double bond together or R₁ is hydrogen or deuterium. R₂ is

and the pharmaceutically acceptable salts formed by it and inorganic acid or organic acid, including the quaternary ammonium salts formed with R₅Z, R₃ and R₄ can be the same or different selected from hydrogen, alkyl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic, trifluoromethyl, polyfluoroalkyl, nitrile group, cyanomethyl, acyl, carbamoyl, sulfonyl, sulfonamide or aryloxyalkyl. R₃, R₄ and N atom form cyclic structure which is preferably 3-member to 9-member ring, where one or more positions on the ring structure can be replaced by the substituent group including hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl or heterocyclic; Z is fluorine, chlorine, bromine, iodine, toluene-p-sulfonate group, mesylate group, benzenesulfonate group or trifluoromethanesulfonate group. R₅ is alkayl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, heterocyclic, aryl-substituting alkyl, arylalkenyl, arylalkynyl, cyano methyl, alkoxy-substituting alkyl or aryloxy substituting alkyl. Inorganic or organic acid can be hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, boric acid, selenious acid, phosphomolybdic acid, phosphorous acid, sulfurous acid, citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, methanesulfonic acid, pentanoic acid, oleic acid, lauric acid, p-toluenesulfonic, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, glycolic acid, a thiol acid, glycine, sarcosine, sulfonic acid, nicotinic acid, picoline acid, isonicotinic, dichloroacetic acid, benzoic acid or substituted benzoic acid. Or R₂ is

where X thereof is O or S, R₆ is hydrogen, alkyl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynylp, heterocyclic, trifluoromethyl, polyfluoroalkyl, nitrile group, cyanomethyl, acyl, carbamoyl, sulfonyl, sulfonamide or aryloxyalkyl.

If there is no bond - - - between R₇ and R₈, R₇ and R₈ will form double bond together or R₇ is methyl, R₈ is hydroxyl or OCOR₉, where R₉ thereof is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic.

If the bond - - - between R₇ and R₈ is single bond, R₇═R₈=methylene.

R₁₀ is hydrogen or R₁₀ and R₈ form single bond.

R₁₁ is hydrogen or R₁₁ and R₁₃ form single bond or epoxy bond.

If these is no bond - - - between R₁₂ and R₁₃, R₁₂ and R₁₃ will form double bond together or R₁₂ is hydroxyl or OR₁₄, where R₁₄ thereof is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, R₁₃ is methyl.

If the bond - - - between R₁₂ and R₁₃ is single bond, R₁₂═R₁₃=methylene.

The structural formula (I) is preferably.

The uses of the above-mentioned compounds in preparing the drugs to treat rheumatoid arthritis.

The uses of the above-mentioned compounds in preparing the adjuvant drugs to treat rheumatoid arthritis.

The uses of the above-mentioned compounds in preparing the drugs to treat cancers through inhibiting cancer stem cells, where the cancers thereof are preferably acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, skin cancer, breast cancer, ovarian cancer, brain tumor, prostate cancer, head and neck squamous cell carcinoma, laryngeal cancer, pancreatic cancer, retinoblastoma, children hepatoblastoma, liver cancer, malignant melanoma, colorectal cancer, colon cancer, glioma, gastrointestinal tumor, nasopharyngeal carcinoma, brain glioma, gastric cancer, lung adenocarcinoma and lung cancer.

The uses of the above-mentioned compounds in preparing the adjuvant drugs to treat cancers through inhibiting cancer stem cells, where the cancers thereof are preferably acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, skin cancer, breast cancer, ovarian cancer, brain tumor, prostate cancer, head and neck squamous cell carcinoma, laryngeal cancer, pancreatic cancer, retinoblastoma, children hepatoblastoma, liver cancer, malignant melanoma, colorectal cancer, colon cancer, glioma, gastrointestinal tumor, nasopharyngeal carcinoma, brain glioma, gastric cancer, lung adenocarcinoma and lung cancer.

The present invention also provides a pharmaceutical composition comprising at least one compound according to any claim of claim 1 to claim 2 as the active component and a pharmaceutically acceptable carrier or other compound(s) to treat rheumatoid arthritis.

The present invention also provides a pharmaceutical composition comprising at least one compound according to any claim of claim 1 to claim 2 as the active component and a pharmaceutically acceptable carrier or other compound(s) to treat cancer.

If the compounds according to the present invention are used as drugs, they can be directly used or in the form of pharmaceutical composition. This pharmaceutical composition comprises the compound according to the present invention with a content of 0.1-99%, preferably 0.5-90% and other pharmaceutical carrier and/or excipient which is pharmaceutically acceptable, nontoxic to human and animal and inert, or is a drug combination with other drug(s) to treat rheumatoid arthritis. The composition according to the present invention can be prepared into the form of injection, tablet or capsule, etc.

Said pharmaceutical carrier or excipient is one or more solids, semi-solids and liquid diluents, fillers and pharmaceutical adjuvants. The pharmaceutical composition according to the present invention is used in the form of dose per unit body weight. The drugs according to the present invention can be delivered in two forms as injection and oral administration, for example, the former can be intravenous and intramuscular injection and the dosage form of the latter can be tablet and capsule.

DETAILED DESCRIPTION OF THE INVENTION

In order to understand the present invention, the following embodiments are used to further describe the present invention. Nevertheless, it is not to limit the protection scope of the present invention.

Embodiment 1 Preparation Method of Compound 1-50

Preparation of Compound 1:

Dissolve the parthenolide (50 mg, 02 mmol) in 2.5 mL CH₂Cl₂ and add p-toluenesulfonic acid (5 mg, 0.026 mmol). Place the reaction system at room temperature and stir it overnight. Transfer the reaction solution into the saturated solution of NaHCO₃ (10 mL), collect the organic phase and extract the aqueous phase with a small amount of CH₂Cl₂, then mix the organic phases together and dry with Na₂SO₄ before filtering it. Distill the organic solvent at reduced temperature with rotary evaporator, then purify it with silica gel column to get Compound 1 (45 mg, yield is 90%). ¹H NMR (CDCl₃, 400 MHz) δ 6.20 (d, J=3.2 Hz, 1H) 5.49 (d, J=32 Hz, 1H) 3.81 (t, J=10.4 Hz, 1H), 270 (d, J=10.4 Hz, 1H), 2.65-2.62 (m, 2H), 2.40-2.34 (m, 1H), 2.07-2.26 (m, 4H), 1.73-1.86 (m, 2H), 1.68 (s, 3H), 1.36-1.28 (m, 4H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.8, 138.7, 131.7, 130.8, 119.5, 84.1, 80.2, 58.5, 49.5, 382, 34.8, 30.0, 25.7, 23.9, 23.6.

Common Preparation Method of Compounds 2-20:

Under the protection by nitrogen gas and in ice-water bath, drip the acyl chloride (RCl) into the mixture of Compound 1 (24.8 mg, 0.1 mmol, DMAP (1.25 mg, 0.01 mmol) and trimethylamine (0.12 mL, 12 mmol), once the dripping ends, remove the ice-water bath and stir the system at room temperature until TLC test confirms the reaction ends. Pour the reaction mixture into ice water and extract with ethyl acetate (5 mL×3), wash the organic layer with citric acid solution (20 mL), saturated NaHCO₃ (10 mL) and saturated saline solution (10 mL) in turn. Dry the organic phase with anhydrous sodium sulfate and concentrate it under reduced pressure to yield the crude product, then separate it with silica gel column chromatography to get pure product.

The yield of Compound 2 is 62.8%. ¹H NMR (400 MHz, CDCl₃z) δ 6.13 (1H, d, J=3.1 Hz), 5.40 (1H, d, J=2.8 Hz) 3.72 (1H, t, J=10.2 Hz) 3.08 (1H, d, J=10.1 Hz) 2.65-2.59(1H, m) 2.41˜2.35 (2H, m), 2.21˜2.13 (4H, m), 2.04˜2.00(1H, m), 1.97 (3H, s), 1.91˜1.83 (1H, m), 1.65 (3H, s), 1.48 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ 169.6, 169.3, 138.4, 130.6, 129.4, 117.8, 87.7, 82.0, 55.6, 49.1, 35.4, 33.9, 29.4, 24.9, 232, 21.5, 17.8.

The yield of Compound 3 is 70.0%, ¹H NMR (400 MHz, CDCl₃) δ6.20 (1H, d, J=3.1 Hz), 5.47 (1H, d, J=2.8 Hz), 3.79 (1H, t, J=10.1 Hz), 3.13 (1H, d, J=10.2 Hz), 2.71˜2.66 (1H, m), 2.49˜2.42 (2H, m), 2.38˜2.30 (2H, m), 2.28˜2.26 (4H, m), 2.11˜2.08 (1H, dd, J=13.8, 1.8 Hz), 1.97˜1.89 (1H, m), 1.72 (3H, s), 1.57 (6H, d, J=9.0 Hz); ¹³C NMR (100 MHz, CDCl3) δ173.8, 170.2, 139.5, 131.5, 130.4, 118.6, 88.4, 83.0, 56.6, 50.1, 36.5, 34.9, 30.4, 28.7, 25.9, 24.1, 18.8, 9.1.

The yield of Compound 4 is 30.0%, ¹H NMR (400 MHz, CDCl₃) δ6.22 (1H, d, J=2.7 Hz), 5.49 (1H, d, J=2.1 Hz), 3.81 (1H, t, J=10.1 Hz), 3.16 (1H, d, J=103 Hz), 2.52˜2.44 (2H, m), 236˜2.23 (6H, m), 2.13˜2.10 (1H, m), 1.99˜1.91 (1H, m), 1.74 (3H, s), 1.70˜1.68 (1H, m), 1.65 (3H, s), 1.57 (2H, s), 0.98 (3H, t, J=73 Hz); ¹³C NMR (100 MHz, CDCl₃) δ173.2, 170.3, 139.5, 131.6, 130.5, 118.7, 88.5, 83.0, 56.8, 50.2, 37.4, 36.6, 35.0, 30.5, 25.9, 242, 18.8, 18.5, 13.6.

The yield of Compound 5 is 37.6%, ¹H NMR (400 MHz, CDCl3) δ6.19 (1, d, J=3.1 Hz), 5.47 (1H, d, J=2.9 Hz), 3.78 (1H, t, J=10.1 Hz), 3.13 (1H, d, J=10.0 Hz), 2.72˜2.66 (1H, m), 2.49˜2.42 (2H, m), 2.37˜2.31 (1H, m), 2.30˜2.26 (4H, m), 2.12˜2.08 (1H, dd, J=13.7, 2.2 Hz), 1.97˜1.88 (1H, m), 1.75 (3H, s), 1.64˜1.56 (2H, m), 1.55 (3H, s), 1.40˜131 (3H, m), 0.92 (3H, t, J=73 Hz); ¹³C NMR (100 MHz, CDCl₃) δ173.4, 1702, 139.5, 131.6, 130.4, 118.7, 88.5, 83.0, 56.8, 50.2, 36.5, 352, 34.9, 30.5, 27.1, 25.9, 24.1, 222, 18.8, 13.8.

The yield of Compound 6 is 26.8%, ¹H NMR (400 MHz, CDCl3) δ6.21 (1H, d, J=3.0 Hz), 5.48 (1H, d, J=2.8 Hz), 3.81 (1H, t, J=10.1 Hz), 3.15 (1H, d, J=10.3 Hz), 2.74˜2.68 (1H, m), 2.57˜2.44 (3H, m), 2.30˜229 (3H, m), 2.14˜2.10 (1H, dd, J=13.7, 2.1 Hz), 1.98˜1.90 (1H, m), 1.74 (3H, s), 1.66 (1H, s), 1.56 (3H, s), 1.21˜1.17 (6H, m); ¹³C NMR (100 MHz, CDCl3) δ176.6, 170.2, 139.6, 131.5, 130.4, 118.6, 882, 83.0, 56.8, 50.1, 36.5, 35.0, 34.7, 30.5, 26.0, 24.2, 19.0, 18.9, 18.7.

The yield of Compound 7 is 47.8% ¹H NMR (400 MHz, CDCl3) δ6.19 (1H, d, J=3.2 Hz), 5.46 (1H, d, J=2.9 Hz), 3.78 (1H, t, J=10.1 Hz), 3.13 (1H, d, J=10.1 Hz), 2.71˜2.66 (1H, m), 2.50˜2.42 (2H, m), 2.28˜2.26 (3H, m), 2.20˜2.07 (4H, m), 1.97˜1.89 (1H, m), 1.72˜1.69 (4H, m), 1.56 (3H, s), 0.97 (6H, d, J=5.9 Hz); ¹³C NMR (100 MHz, CDCl3) δ172.7, 170.2, 139.5, 131.6, 130.5, 118.7, 88.5, 83.0, 56.8, 502, 44.6, 36.6, 35.0, 30.5, 25.9, 25.8, 24.2, 22.4, 22.3, 18.8.

The yield of Compound 8 is 13.9% ¹H NMR (400 MHz, CDCl3) δ6.20 (1H, d, J=2.9 Hz), 5.47 (1H, d, J=2.4 Hz), 4.07˜3.95 (2H, q, J=16.4 Hz), 3.79 (1H, t, J=10.1 Hz), 3.47 (3H, s), 3.19 (1H, d, J=10.1 Hz), 2.71˜2.66 (1H, m), 2.51˜2.44 (2H, m), 2.27 (3H, s), 2.11˜2.08 (1H, dd, J=12.5, 0.7 Hz), 2.04˜1.95 (1H, m), 1.72 (3H, s) 1.63 (1H, s), 1.58 (3H, s); ¹³C NMR (100 MHz, CDCl3) δ170.2, 169.7, 139.3, 131.9, 130.0, 118.9, 89.6, 82.9, 70.3, 59.3, 56.4, 50.0, 36.4, 35.0, 30.4, 25.9, 242, 18.9.

The yield of Compound 9 is 56.2%, ¹H NMR (400 MHz, CDCl3) δ6.23 (1H, d, J=33 Hz), 5.50 (1H, d, J=3.1 Hz), 4.14˜4.05 (2H, m), 3.81 (1H, t, J=10.1 Hz), 3.20 (1H, d, J=10.0 Hz), 2.74˜2.68 (1H, m), 2.54˜2.47 (2H, m), 2.30˜2.29 (3H, m), 2.15˜2.11 (1H, dd, J=13.8, 2.3 Hz), 2.07˜1.97 (1H, m), 1.75 (3H, s), 1.62 (4H, s); ¹³C NMR (100 MHz, CDCl3) δ170.1, 166.4, 139.2, 132.1, 129.8, 119.0, 90.8, 82.8, 56.4, 50.1, 42.0, 363, 35.0, 303, 25.9, 242, 18.8.

The yield of Compound 10 is 20.7%, ¹H NMR (400 MHz, CDCl3) δ6.23 (1H, d, J=3.3 Hz), 5.96 (1H, s), 5.51 (1H, d, J=3.0 Hz), 3.81 (1H, t, J=10.1 Hz), 3.21 (1H, d, J=10.1 Hz), 2.76˜2.70 (1H, m), 2.56˜2.48 (2H, m), 2.30 (3H, s), 2.15˜2.11 (1H, dd, J=13.8, 2.3 Hz), 2.07˜1.99 (1H, m), 1.75 (3H, s), 1.66 (4H, s); ¹³C NMR (100 MHz, CDCl3) δ169.9, 163.4, 139.2, 132.4, 129.5, 119.0, 923, 82.5, 65.2, 56.5, 50.1, 36.0, 34.9, 302, 25.9, 24.1, 18.6.

The yield of Compound 11 is 46.5% ¹H NMR (400 MHz, CDCl3) δ6.22 (1H, d, J=3.3 Hz), 5.49 (1H, d, J=3.0 Hz), 3.86 (2H, s), 3.80 (1H, J=10.1 Hz), 3.18 (1H, d, J=9.9 Hz), 2.74˜2.68 (1H, m), 2.53˜2.46 (2H, m), 230˜2.29 (3H, m), 2.14˜2.10 (1H, dd, J=13.8, 2.3 Hz), 2.06˜1.94 (1H, m), 1.74 (3H, s), 1.71 (1H, s), 1.60 (3H, s); ¹³C NMR (100 MHz, CDCl3) δ170.1, 166.3, 139.3, 132.1, 129.9, 118.9, 90.8, 82.8, 56.5, 50.1, 36.2, 34.9, 303, 27.7, 25.9, 24.2, 18.7.

The yield of Compound 12 is 25.8% ¹H NMR (400 MHz, CDCl3) δ6.22 (1H, d, J=3.2 Hz), 5.49 (1H, d, J=2.8 Hz), 3.81 (1H, t, J=102 Hz), 3.47 (2H, t, J=6.5 Hz), 3.15 (1H, d, J=10.0 Hz), 2.73˜2.68 (1H, m), 2.51˜2.44 (2H, m), 2.40˜2.32 (2H, m), 2.30 (2H, d, J=6.4 Hz), 2.14˜2.10 (1H, dd, J=13.7, 1.9 Hz), 1.99˜1.91 (3H, m), 1.83˜1.78 (2H, m), 1.74 (3H, s), 1.60 (3H, s), 1.57 (2H, s); ¹³C NMR (100 MHz, CDCl3) δ172.5, 170.2, 139.4, 131.7, 130.2, 118.8, 88.75, 83.0, 56.7, 50.1, 36.5, 35.0, 34.5, 33.5, 32.0, 30.5, 25.9, 24.2, 23.6, 18.8.

The yield of Compound 13 is 47.6% ¹H NMR (400 MHz, CDCl3) δ6.22 (1H, d, J=3.3 Hz), 5.49 (1H, d, J=3.0 Hz), 3.81 (1H, t, J=102 Hz), 3.37˜3.33 (2H, m), 3.16 (1H, d, J=10.1 Hz), 2.74˜2.68 (1H, m), 2.51˜2.45 (2H, m), 2.41˜233 (2H, m), 2.31˜2.29 (3H, m), 2.14˜2.10 (1H, dd, J=13.7, 2.2 Hz), 2.00˜1.92 (1H, m), 1.74 (3H, s), 1.73˜1.66 (4H, m), 1.62 (1H, s), 1.57 (3H, s); ¹³C NMR (100 MHz, CDCl3) δ171.5, 169.2, 138.4, 130.7, 129.2, 117,7, 87.7, 82.0, 55.7, 50.1, 49.1, 35.5, 34.0, 33.9, 29.4, 272, 24.9, 23.1, 212, 17.8.

The yield of Compound 14 is 78.2%, ¹H NMR (400 MHz, CDCl3) δ6.47˜6.37 (1H, dd, J=17.3, 1.3 Hz), 6.21 (1H, d, J=33 Hz), 6.13˜6.06 (1H, m), 5.80˜5.77 (1H, dd, J=10.3, 1.3 Hz), 5.48 (1H, d, J=3.1 Hz), 3.82 (1H, J=10.1 Hz), 3.15 (1H, d, J=10.1 Hz), 2.73˜2.67 (1H, m), 2.58˜2.44 (2H, m), 2.29˜2.27 (3H, m), 2.12˜2.08 (1H, dd, J=13.7, 2.3 Hz), 2.00˜1.92 (1H, m), 1.73 (3H, s), 1.59 (4H, s); ¹³C NMR (100 MHz, CDCl3) δ170.3, 165.5, 139.4, 131.7, 130.2, 130.1, 130.0, 118.8, 88.8, 83.0, 57.1, 50.1, 36.5, 35.0, 30.5, 25.9, 242, 18.6.

The yield of Compound 15 is 13.5%, ¹H NMR (400 MHz, CDCl3) δ6.22 (1H, d, J=3.3 Hz), 5.49 (1H, d, J=3.0 Hz), 5.20 (1H, d, J=5.0 Hz), 5.16 (1H, s), 3.81 (1H, t, J=10.1 Hz), 3.16 (1H, d, J=8.8 Hz), 3.12˜3.09 (2H, m), 2.74˜2.68 (1H, m), 2.51˜2.44 (2H, m), 230˜2.28 (4H, m), 2.14˜2.10 (1H, dd, J=13.7, 2.1 Hz), 2.00˜1.92 (1H, m), 1.88˜1.86 (1H, dd, J=6.9, 1.3 Hz), 1.74 (3H, s), 1.59 (1H, s), 1.58 (3H, s); ¹³C NMR (100 MHz, CDCl3) δ171.0, 170.2, 139.5, 131.7, 130.7, 1303, 118.7, 118.2, 89.0, 83.0, 56.7, 50.1, 402, 36.5, 35.0, 30.5, 25.9, 24.2, 18.8.

The yield of Compound 16 is 26.6%, ¹H NMR (400 MHz, CDCl3) δ6.20 (1H, d, J=3.2 Hz), 5.68 (1H, s), 5.47 (H, d, J=2.8 Hz), 3.81 (1H, t, J=10.2 Hz), 3.15 (1H, d, J=10.0 Hz), 2.73˜2.67 (1H, m), 2.57˜2.43 (2H, m), 2.28˜2.27 (3H, m), 2.15 (3H, s), 2.12˜2.08 (1H, dd, J=13.9, 2.1 Hz), 2.00˜1.92 (2H, m), 1.87 (3H, s), 1.73 (3H, s), 1.59 (3H, s); ¹³C NMR (100 MHz, CDCl3) δ170.3, 166.2, 155.4, 139.5, 131.5, 130.6, 118.7, 117.7, 882, 83.1, 57.0, 503, 36.8, 34.9, 30.6, 27.4, 25.9, 242, 20.1, 18.9.

The yield of Compound 17 is 23.3%, ¹H NMR (400 MHz, CDCl3) δ7.76 (1H, d, J=16.0 Hz), 7.59˜7.57 (2H, m), 7.39 (3H, d, J=5.0 Hz), 6.45 (1H, d, J=16.0 Hz), 6.24 (1H, d, J=3.1 Hz), 5.51 (1H, d, J=2.7 Hz), 3.88 (1H, t, J=10.2 Hz), 3.20 (1H, d, J=10.0 Hz), 2.78˜2.73 (1H, m), 2.65˜2.61 (1H, m), 2.55˜2.48 (1H, m), 2.31 (3H, s), 2.16 (1H, d, J=13.5 Hz), 2.07˜1.98 (1H, q), 1.75 (3H, s), 1.63 (4H, s); ¹³C NMR (100 MHz, CDCl3) δ170.4, 166.4, 144.5, 139.5, 134.7, 131.6, 130.0, 129.9, 128.8, 128.2, 119.7, 118.8, 88.7, 83.1, 573, 50.0, 36.7, 35.0, 30.6, 26.0, 24.2, 18.6.

The yield of Compound 18 is 53.3% ¹H NMR (400 MHz, CDCl3) δ 6.18 (1H, d, J=3.2 Hz), 5.87˜5.80 (1H, m), 5.46 (1H, d, J=3.0 Hz), 5.09 (1H, d, J=16.9 Hz), 5.00 (1H, d, J=9.6 Hz), 3.80˜3.74 (1H, m), 3.12 (1H, d, J=7.4 Hz), 2.68 (1H, s), 2.45˜2.40 (3H, m), 2.37 (4H, s), 2.25 (3H, s), 2.11˜2.07 (1H, m), 1,95˜1.89 (1H, m), 1.71 (3H, s), 1.54 (3H, d, J=3.8 Hz): ¹³C NMR (100 MHz, CDCl3) δ172.4, 170.2, 139.5, 136.9, 131.6, 1303, 118.7, 1153, 88.7, 82.9, 56.7, 50.1, 36.5, 35.0, 34.6, 30.4, 29.0, 25.9, 24.2, 18.8.

The yield of Compound 19 is 65.2%, ¹H NMR (400 MHz, CDCl3) δ6.21 (1H, d, J=3.1 Hz), 5.49 (1H, d, J=2.7 Hz), 3.82 (1H, t, J=10.0 Hz), 3.15 (1H, d, J=93 Hz), 2.91˜2.82 (3H, m), 2.14˜2.10 (1H, m), 2.04˜2.01 (3H, m), 1.97˜1.87 (8H, m), 1.83˜1.75 (6H, m), 1.63 (1H, s); ¹³C NMR (100 MHz, CDCl3) δ172.4, 170.2, 139.4, 131.7, 130.2, 118.8, 88.8, 83.6, 83.0, 69.0, 56.7, 50.1, 36.5, 34.9, 34.1, 30.5, 25.9, 242, 23.7, 18.8, 17.8.

The yield of Compound 20 is 24.0%, ¹H NMR (400 MHz, CDCl3) δ7.32˜7.18 (5H, m), 6.22 (1H, d, J=33 Hz), 5.49 (1H, d, J=3.0 Hz), 3.80 (1H, t, J=10.1 Hz), 3.12 (1H, d, J=10.1 Hz), 2.99 (2H, t, J=7.9 Hz), 2.73˜2.59 (3H, m), 2.49˜2.43 (2H, m), 230˜2.28 (3H, m), 2.14˜2.10 (1H, dd, J=13.8, 2.3 Hz), 1.96˜1.87 (1H, m), 1.74 (3H, s), 1.65 (1H, s), 1.56 (3H, s): ¹³C NMR (100 MHz, CDCl3) δ172.3, 170.2, 140.8, 139.5, 131.6, 130.4, 128.4, 126.0, 118.7, 88.8, 83.0, 56.7, 50.1, 36.8, 36.5, 35.0, 31.0, 30.5, 26.0, 24.2, 18.8.

Synthesis of Compound 21:

In one dry and clean reaction flask of 10 mL, add 5-acetylenic acid and Compound 19 (200 mg, 0.584 mmol), 6-azido-1-n-hexanol (125.43 mg, 0.876 mmol), copper sulfate hydrate (145.80 mg, 0.584 mmol) and sodium ascorbate (462.78 mg, 2.336 mmol), then add the mixture solution of distilled water and tert-butyl alcohol (1:2) (3 mL) to dissolve them to homogeneous phase and then stir it for 2 hours at room temperature. Remove partial solvent with rotary evaporator and extract the remaining reaction solution mixture with ethyl acetate, then collect the organic phase and dry with anhydrous sodium sulfate and filter at reduced pressure. Dry the organic phase with rotary evaporator and separate it with silica column chromatography to get Compound 21 (120.0 mg) with a yield of 61.3%. ¹H NMR (400 MHz, CDCl3) δ7.52 (1H, s), 6.20 (1H, d, J=3.3 Hz), 5.49 (1H, d, J=3.0 Hz), 4.34 (2H, t, J=7.1 Hz), 3.81 (1H, t, J=10.2 Hz), 3.63 (2H, t, J=6.4 Hz), 3.14 (1H, d, J=10.1 Hz), 2.81˜2.76 (2H, m), 2.74˜2.67 (1H, m), 2.51˜2.43 (2H, m), 239˜231 (2H, m), 2.29˜2.27 (4H, m), 2.13˜2.09 (1H, dd, J=13.8, 2.3 Hz), 2.05˜2.00 (3H, m), 1.97˜1.88 (5H, m), 1.72 (4H, s), 1.60˜1.53 (6H, m); ¹³C NMR (100 MHz, CDCl3) δ172.6, 170.2, 147.1, 139.4, 131.7, 130.0, 1213, 118.8, 88.6, 83.1, 622, 56.7, 50.0, 49.9, 36.4, 34.9, 34.7, 32.3, 30.4, 30.1, 26.1, 25.8, 25.1, 24.8, 24.7, 24.1, 18.8.

Preparation of Compound 22:

Mix dimethylamine hydrochloride (1.5 g, 18 mmol) and K₂CO₃ (5.0 g, 36 mmol) and then add them into 100 ml CH₂Cl₂ to stir 15 minutes, then filter under pressure and directly add into Compound 5 (300 mg, 12 mmol) and stir for 3 h at room temperature. Remove the solvent at reduced pressure and dissolve it with a few amount of CH₂Cl₂, wash it three times rapidly with water and dry with Na₂SO₄ before filer it, then remove the CH₂Cl₂ at reduced pressure to obtain the crude product—dimethyl amine intermediate. Dissolve it again with a few amount of CH₂Cl₂ and add the dilute hydrochloric acid solution (equivalent to dimethyl amine intermediate) with stirring where the pH value of aqueous solution shall be tested during stirring and the dripping of hydrochloric acid solution shall be stopped when it becomes 4-5. Collect the aqueous phase and dry it through freezing to get Compound 22.

Dimethyl amine intermediate: ¹H NMR (CDCl₃, 400 MHz) δ 3.76 (t, J=10.0 Hz, 1H), 2.96 (s, 1H), 2.49-2.67 (m, 3H), 2.28-2.34 (m, 1H), 2.30-2.34 (m, 2H) 2.18 (s, 6H), 2.09 (br s, 2H), 1.96 (d, J=11.2 Hz, 1H) 1.67-1.73 (m, 2H) 1.60 (s, 3H), 1.22 (br s, 3H), 1.18 (br s, 2H); 13C NMR (CDCl₃, 300 MHz) δ 177.0, 131.8, 131.3, 84.0, 80.2, 58.3, 58.1, 50.9, 46.0, 44.6,38.4, 353, 30.0, 272, 23.7, 22.8.

Compound 22: [α]_(D) ²⁰=−42.0 (c=10, H₂O); IR (KBr): 3334, 2927, 2856, 1767, 1467, 992, 967, 874, 831, 719, 669, 626, 504 cm-1; ¹H NMR (D₂O, 400 MHz) δ 4.14 (t, J=10.3 Hz, 1H), 3.51 (q, J=12.6 Hz, 1H), 3.40 (dd, J=13.3, 2.9 Hz, 1H), 3.18-3.04 (m, 1H), 2.96 (d, J=10.6 Hz, 6H), 2.67 (d, J=10.2 Hz, 1H), 2.37 (dd, J=16.2, 8.1 Hz, 1H), 2.27-2.05 (m, 4H), 1.87 (d, J=12.9 Hz, 1H), 1.73 (dd, J=19.5, 11.7 Hz, 2H), 1.66 (s, 3H), 1.46-131 (m, 2H), 1.26 (s, 3H) ¹³C NMR (CDCl₃, 100 MHz) δ 178.4, 132.6, 131.4, 85.1, 80.7, 56.9, 55.6, 49.9, 45.1, 42.3, 41.5, 39.2, 34.4, 29.5, 25.9, 23.2, 21.4. HRMS calcd for C₁₇H₂₇NO₃ [M⁺H]⁺ 294.1991, found 294.2069.

Preparation of Compound 23:

Mix dimethylamine hydrochloride (1.5 g, 18 mmol) and K₂CO₃ (5.0 g, 36 mmol) and then add them into 10 ml CH₂Cl₂ to stir 15 minutes, then filler under pressure and directly add into Compound 5 (300 mg, 1.2 mmol) and stir for 3 h at room temperature. Remove the solvent at reduced pressure and dissolve it with a few amount of CH₂Cl₂, then wash it three times rapidly with water and dry with Na₂SO₄ before filter it. Remove the CH₂Cl₂ at reduced pressure to yield the crude product—dimethyl amine intermediate, then dissolve it again with a few amount of CH₂Cl₂ and add fumaric acid (equivalent to dimethyl amine intermediate) with stirring. Then concentrate and dry it to get Compound 23. ¹H NMR (DMSO, 400 MHz) δ 6.58 (s, 2H), 3.80 (t, J=10.3 Hz, 1H), 2.64 (s, 3H), 2.49-2.53 (m, 3H), 2.26-2.27 (m, 1H), 2.23 (s, 6H), 1.96-2.10 (m, 6H), 1.60 (s, 3H), 1.57-1.59 (m, 2H), 1.23-1.25 (m, 1H), 1.15 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) 177.8, 167.6, 1352, 133.7, 131.4, 83.4, 8031, 58.0, 57.1, 51.7, 45.2, 43.6, 41.0, 353, 302, 27.0, 242, 232.

Preparation of Compound 24:

Dissolve Compound 1 (628 mg, 12.5 mmol) in 35 ml CH₂Cl₂ and then add m-CPBA (680 mg, 4.0 mmol). Place and stir the reaction system at room temperature and monitor the reaction with TCL. After the raw materials disappear, pour the reaction mixture into 5% NaHCO₃ (60 mL) and wash the organic phase with water (20 ml), then collect the organic phase and dry it with Na₂SO₄ before filer it, then dry it through rotary evaporation to get the crude product, then purity it with silica gel column to get Compound 24. ¹H NMR (CDCl₃, 400 MHz) δ 6.17 (d, J=32 Hz, 1H), 5.47 (d, J=2.8 Hz, 11H), 4.04 (t, J=10.8 Hz, 1H, 2.36-2.20 (m, 4H), 2.03-1.08 (m, 4H), 1.68-1.62 (m, 1H), 1.46 (s, 3H), 1.46 (d, J=12.8 Hz, 1H), 1.29 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.5, 137.9, 119.5, 81.7, 79.5, 69.7, 62.1, 55.3, 49.2, 37.2, 33.2, 29.3, 23.1, 23.0, 21.8.

Preparation of Compound 25:

According to the paper “Hongquan Yin, Xiulan Qi, Huiming Hua, Yuehu Pei, Study on Chemical Ingredients of Aplotaxis Auriculata, Chin J Med Chem, 2005, Vol 15, No. 4, P217-220”, it is produced through separating and purifying from aplotaxis auriculata.

Preparation of Compound 26 and Compound 30:

Stir the methanol solution of Compound 25 (150 mg, 0.65 mmol) and sodium methoxide (20 mg, 0.37 mmol) at 30° C. for 10 hours. After TLC test is finished, pour the reaction solution into ice water, extract it with ethyl acetate four times and mix the layers of ethyl acetate, then wash it with 5% hydrochloric acid, saturated NaHCO₃ aqueous solution and saturated saline solution in turn. Dry with anhydrous magnesium sulfate, then filter, concentrate and purify it with silica gel column to get the methoxylation product (136 mg, 80%).

¹H-NMR (400 MHz, CDCl₃) δ 5.19 (d, J=1.6 Hz, 1H) 5.03 (d, J=1.6 Hz, 1H), 4.87 (s, 1H), 4.76 (s, 1H, 3.93 (t, J=9.2 Hz, 1H), 3.70 (dd, J=4.4, 9.8 Hz, H), 3.63 (dd, J=3.2, 9.8 Hz, 1H), 3.37 (s, 3H), 2.90 (m, 1H), 2.83 (m, 1H), 2.51 (m, 2H), 2.49 (m, 1H), 2.44 (m, 1H), 2.38 (m, 1H), 2.19 (m, 1H), 2.07 (m, 1H), 1.95 (m, 1H), 1.86 (m, 1H), 1.32 (m, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ 175.7, 151.8, 149.9, 111.5, 108.8, 85.3, 68.9, 59.0, 51.7, 47.7, 46.9, 43.9, 37.7, 32.5, 32.4, 30.1.

Add Zn—Cu alloy (812 mg) and anhydrous ether (4 mL) in a dual-port bottle connected with condenser pipe and dry pipe, then add one granule of iodine and stir it until the color of iodine disappears. Add the ether solution (2 mL) of methoxylation product (262 mg, 1 mmol) and diiodomethane (0.8 mL, 10 mmol) and then reflux it for 72 hours. After TLC shows the reaction is completed, pour out the ether solution and wash the residual solid two times with ether (3 mL), mix the ether layers and wash it respectively with saturated NH₄Cl aqueous solution and water (10 mL) then dry it with anhydrous sodium sulfate before filter and concentrate. Purify it with chromatography column to get the product which is white solid Compound 30 (206 mg, 71%). ¹H-NMR (400 MHz, CDCl₃) δ 4.20 (m, 1H), 3.65 (dd, J=3.9, 9.9 Hz, 1H), 3.59 (dd, J=3.0, 9.9 Hz, 1H), 3.34 (s, 1H), 2.30-2.40 (m, 3H), 1.92-2.07 (m, 2H), 1.15-1.70 (m, 7H), 0.85 (m, 1H), 0.70 (m, 1H), 0.50 (m, 1H), 0.40 (m, 1H), 0.16-0.36 (m, 4H); ¹³C-NMR (100 MHz, CDCl₃) δ 176.4, 83.9, 69.2, 59.2, 51.5, 47.9, 473, 443, 36.2, 35.9, 29.0, 273, 26.7, 18.5, 12.5, 10.4, 10.0, 8.8; ESI-HRMS m/z: 291.1964 [M+H].

Dissolve Compound 30 (0.023 g, 0.080 mmol) in acetonitrile (0.52 mL), then add 4M NaOH aqueous solution (0.11 mL) and reflux 5 hours, after TLC test shows the reaction is completed, cool it to room temperature before add 10% hydrochloric acid to adjust the pH value to 3. Add ethyl acetate (20 mL) and wash twice with water (2×20 mL), then extract the aqueous phase twice with ethyl acetate(2×20 mL), mix the organic layers and dry it with anhydrous sodium sulfate, then filter and concentrate it before separate with chromatography column to get the product which is white solid 26 (0.019 g, 94%).

Molecular formula: C₁₇H₂₂O₂

Molecular weight: 258

Form: white amorphous powder

Spectrum data:

¹H-NMR (400 MHz, CDCl₃) δ 6.17 (d, J=3.2 Hz, 1H), 5.45 (d, J=3.2 Hz, 1H), 4.24 (dd, J=8.8, 10.8 Hz, 1H), 2.87 (m, 1H), 2.20 (m, 1H), 2.07 (m, 1H), 1.95 (dd, J=8.8, 10.4 Hz, 1H), 1.71 (m, 2H), 1.37-1.61 (m, 5H), 0.98 (m, 1H), 0.64 (m, 1H), 0.49 (m, 1H), 0.43 (m, 1H), 0.27-0.37 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 139.4, 118.5, 82.5, 51.6, 47.4, 442, 34.2, 32.8, 26.4, 26.2, 25.3, 17.4, 11.1, 10.7, 10.5, 7.8; ESI-HRMS m/z: 259.1692 [M+H].

Preparation of Compound 27:

Suspend dimethylamine hydrochloride (245 mg) in 11 mL CH₂Cl₂ solution, then add K₂CO₃ (380 mg) and stir 0.5 hour, then add Compound 26 (42 mg) and reflux 4 hours, then separate with silica gel column (petroleum ether ethyl acetate:=70:30) to get the oily Compound 27 with the yield: 78%

Molecular formula: C₁₉H₂₉NO₂

Molecular weight: 303

Form: oily liquid

Spectrum data:

¹H-NMR (400 MHz, CDCl₃) δ4.19 (dd, J=9.5, 102 Hz, 1H), 2.66 (dd, J=12.8, 4.8 Hz, 1H), 2.49 (dd, J=12.8, 6.8 Hz, 1H), 2.25-2.38 (m, 2H), 2.21 (s, 6H), 1.98-2.12 (m, 2H), 1.80-1.84 (m, 1H), 1.68 (m, 1H), 1.27-1.48 (m, 5H), 1.11 (m, 1H), 1.01 (m, 1H), 0.69 (m, 1H), 0.46 (m, 1H), 0.18-137 (m, 4H), 0.11 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 181.3, 82.8, 58.0, 50.8, 46.4, 46.0, 45.0, 44.6, 35.2, 34.9, 28.2, 26.3, 25.7, 17.5, 11.5, 9.6, 92, 7.9; ESI-HRMS m/z: 304.2273 [M+H].

Synthesis Method of Compound 28:

Dissolve Compound 27 (38 mg) in 2 mL CH₂Cl₂. Slowly add 0.05 M dilute hydrochloric acid with stirring until the pH value becomes 4. Separate the aqueous phase, wash once with CH₂Cl₂. Freeze, and dry the aqueous phase to get Compound 28 (31 mg) with a yield of 73%.

Molecular formula: C₁₉H₃₀NO₂Cl

Molecular weight: 339

Form: White solid

Spectrum data:

¹H-NMR (400 MHz, D₂O) δ 4.42 (m, 1H), 331-337 (m, 1H), 3.21-3.25 (n, 1H), 2.92 (m, 1H), 2.82 (s, 3H), 2.80 (s, 3H), 2.11-2.26 (m, 2H), 1.94 (m, 1H), 1.79 (m, 11H), 1.39-1.58 (m, 5H), 1.23 (m, 1H), 1.13 (m, 1H), 0.69 (m, 1H), 0.46 (m, 1H, 0.18-1.33 (m, 4H), 0.11 (m, 2H); ¹³C NMR (100 MHz, D₂O) 178.2, 85.8, 56.0, 51.0, 47.2, 45.9, 44.8, 42.5, 42.2, 35.7, 35.2, 27.5, 272, 26.6, 183, 12.2, 103, 9.8, 8.6; ESI-HRMS m/z: 304.2271 [M+H].

Synthesis of Compound 29:

Add 20 mg Compound 26 into the reaction flask and dissolve it with 1 mL THF, then add 86 mg proline ethyl ester hydrochloride and 0.2 mL DBU, stir for 24 hours before purify it with chromatography column to get Compound 29 (12 mg) with a yield: 39%.

Molecular formula: C₂₄H₃₅NO₄

Molecular weight: 401

Form: colorless oily compound

Spectrum data:

¹H NMR (400 MHz, CDCl₃): δ 4.10-4.22 (m, 3H) 3.31 (dd, J=8.8, 5.2 Hz, 1H), 3.05 (dd, J=13.2, 5.2 Hz, 1H), 2.91-2.96 (m, 1H), 2.86 (dd, J=132, 3.6 Hz, 1H), 2.37-2.49 (m, 3H) 2.23-2.29 (m, 1H) 1.96-2.11 (m, 3H), 1.73-1.94 (m, 3H), 1.57-1.69 (m, 3H), 1.40 -1.47 (m, 1H), 1.17-136 (m, 6H), 0.83-0.89 (m, 1H), 0.70-0.75 (m, 1H), 0.48-0.53 (m, 1H), 0.40-0.45 (m, 1H), 0.26-036 (m, 2H), 0.17-0.24 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 178.3, 174.4, 843, 66.6, 60.6, 53.9, 51.9, 51.7, 47.5, 472, 44.7, 36.6, 362, 293, 29.1, 27.6, 27.0, 24.0, 18.8, 14.5, 12.8, 10.6, 10.1, 9.1; ESI-HRMS m/z: 402.2644 [M+H].

Synthesis Method of Compound (31):

Weigh Compound 26 (51.6 mg) and dissolve DMAP (4 mg) in 2 mL CH₂Cl₂, then add 66 mg thiophenol and stir 12 hours, dry it through rotary evaporation and purify it with silica column chromatography to get Compound 31(68 mg).

¹H NMR (400 MHz, CDCl₃) δ 7.44-7.34 (m, 2H), 7.30 (dd, J=10.3, 4.8 Hz, 2H), 7.20 (t, J=7.3 Hz, 1H), 4.24-4.14 (m, 1H), 3.47 (dd, J=13.8, 4.0 Hz, 1H), 3.11 (dd, J=13.8, 7.0 Hz, 1H), 2.52 (ddd, J=11.2, 7.0, 4.1 Hz, 1H), 2.30 (ddd, J=20.7, 10.6, 4.2 Hz, 1H), 2.21 (dd, J=18.2, 8.9 Hz, 1H), 2.13-2.03 (m, 1H), 1.96-1.86 (m, 1H), 1.73-1.63 (m, 1H), 1.61-1.47 (m, 2H), 1.43 (ddd, J=12.3, 8.5, 3.5 Hz, 1H), 1.39-1.25 (m, 3H), 0.89 (dt, J=9.8, 4.8 Hz, 1H), 0.65 (ddd, J=9.2, 5.4, 3.8 Hz, 1H), 0.42 (tt, J=13.4, 4.6 Hz, 2H), 0.36-0.30 (m, 1H), 0.29-0.21 (m, 2H), 0.18-0.08 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 177.1, 136.3, 130.0, 129.6, 127.0, 84.2, 77.92, 52.6, 48.3, 47.4, 47.1, 35.9, 35.4, 33.8, 29.7, 27.7, 27.0, 18.8, 12.8, 11.4, 9.3.

Synthesis Method of Compound (32):

Dissolve Compound 26 (51.6 mg) and 1,8-Diazabicyclo(5.4.0)undec-7-ene (15.2 mg) in 0.5 mL acetonitrile, then add 37.3 mg benzyl mercaptane and stir 24 hours, then dry through rotary evaporation, then purify it with silica column chromatography to get Compound 32 (75 mg). ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.23 (m, 4H), 7.22-7.17 (m, 1H), 4.13 (t, J=9.9 Hz, 1H), 3.77-3.63 (m, 2H), 2.80-2.66 (m, 2H), 2.35 (dt, J=10.5, 5.1 Hz, 1H), 2.28-2.14 (m, 2H), 1.89 (ddd, J=14.0, 10.1, 5.2 Hz, 2H), 1.67-1.49 (m, 2H), 1.48-1.38 (m, 2H), 1.38-1.30 (m, 1H), 1.30-1.17 (m, 2H), 0.83 (dt, J=9.7, 4.9 Hz, 1H), 0.63 (ddd, J=9.4, 5.4, 4.0 Hz, 1H), 0.48-0.40 (m, 1H), 0.36 (dt, J=8.9, 4.5 Hz, 1H), 0.33-0.25 (m, 1H), 0.24-0.13 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 177.4, 138.6, 129.5, 129.0, 127.6, 84.3, 52.2, 48.0, 47.7, 46.8, 38.1, 36.1, 36.0,30.7, 29.6, 27.8, 27.1, 18.9, 13.0, 11.2, 11.0, 9.3.

Synthesis Method of Compound (33):

Dissolve Compound 26 (51.6 mg) in 1 mL methanol, then add 321 mg benzylamine and stir 24 hours, then dry it through rotary evaporation, then purify it with silica column chromatography to get the intermediate (76 mg). Dissolve it in 5 mL methanol and add 21 mg methane sulfonic acid, then stir it 10 minutes and dry with dry evaporation to get Compound 33 (97 mg).

¹H NMR (400 MHz, MeOD) δ 7.47 (d, J=38.9 Hz, 5H), 4.41 (t, J=9.9 Hz, 1H), 4.27 (q, J=13.1 Hz, 2H), 3.26 (s, 1H), 2.93-2.79 (m, 1H), 2.67 (s, 3H), 2.39-2.28 (m, 1H), 2.17 (t, J=16.3 Hz, 1H), 2.04 (t, J=9.7 Hz, 1H), 1.86 (d, J=8.2 Hz, 1H), 1.60 (dd, J=17.1, 7.0 Hz, 2H), 1.45 (d, J=35.5 Hz, 3H), 1.30 (dt, J=28.7, 13.8 Hz, 3H), 0.83 (d, J=4.0 Hz, 1H), 0.62 (s, 1H), 0.48 (d, J=3.8 Hz, 1H), 0.41 (d, J=3.9 Hz, 1H), 0.30 (d, J=4.0 Hz, 2H), 0.21 (s, 2H); ¹³C NMR (100 MHz, MeOD) δ 178.38, 132.13, 131.14, 130.72, 130.28, 86.43, 52.59, 52.52, 48.62, 46.81, 46.39, 44.39, 39.60, 36.78, 36.68, 29.12, 28.21, 27.69, 19.31, 13.06, 11.09, 10.81, 9.44.

Synthesis Method of Compound (34):

Dissolve Compound 26 (103 mg) in 2 mL methanol, add 366 mg aminoethanol and stir 24 hours, then purify it with silica column chromatography to get 118 g amine addition intermediate, then dissolve it in 5 mL methanol and add 35.6 mg methane sulfonic acid, then stir it 10 minutes and dry with dry evaporation to get Compound 34 (153 mg).

¹H NMR (400 MHz, D₂O) δ 4.60 (t, J=10.1 Hz, 1H), 3.85 (t, J=5.0 Hz, 2H), 3.41-3.31 (m, 2H), 3.29-3.18 (m, 2H), 2.97-2.84 (m, 1H), 2.78 (s, 3H), 2.33 (q, J=8.8 Hz, 2H), 2.03 (t, J=9.8 Hz, 1H), 1.96-1.86 (m, 1H), 1.67 (dd, J=11.8, 7.7 Hz, 1H), 1.59-1.37 (m, 5H), 1.35-1.23 (m, 1H), 0.83-0.74 (m, 1H), 0.55-0.38 (m, 3H), 0.38-0.25 (m, 3H), 0.24-0.19 (m, 1H):

¹³C NMR (100 MHz, D₂O) δ 178.39, 85.67, 56.28, 50.62, 49.68, 46.96, 45.74, 45.67, 43.11, 38.58, 35.95, 35.62, 27.66, 27.22, 26.69, 18.27, 12.28, 10.14, 9.49, 8.72.

Synthesis Method of Compound (35):

Weigh Compound 26 (103 mg) and dimethylamine hydrochloride (489 mg) to dissolve in 20 mL CH₂Cl₂, add 1.66 g K₂CO₃ and reflux 6 hours, filter it before drying it through rotary evaporation, and then purify it with silica column chromatography to get Compound 27 (110 mg). Weigh 49 mg Compound 27 to dissolve in 1 mL methanol and add 20.9 mg dichloroacetic acid before stir 10 minutes, and then dry it through rotary evaporation to get Compound 35 (69 mg).

¹H NMR (400 MHz, MeOD) δ 5.91 (s, 1H), 4.41 (t, J=10.1 Hz, 1H), 3.37 (dd, J=13.3, 9.2 Hz, 1H), 3.22 (dd, J=13.3, 4.0 Hz, 1H), 2.98-2.91 (m, 1H), 2.85 (s, 6H), 2.35 (dd, J=17.4, 9.1 Hz, 1H), 2.25-2.14 (m, 1H), 2.08-2.00 (m, 1H), 1.98-1.88 (m, 1H), 1.69-1.56 (m, 2H), 1.56-1.44 (m, 3H), 1.40-1.22 (m, 2H), 0.85 (dt, J=9.6, 4.8 Hz, 1H), 0.63 (ddd, J=9.3, 5.4, 3.9 Hz, 1H), 0.52-0.46 (m, 1H), 0.45-0.39 (m, 1H), 0.35-0.29 (m, 2H), 0.21 (td, J=9.5, 5.2 Hz, 2H); ¹³C NMR (100 MHz, MeOD) δ 178.45, 170.46, 86.32, 70.47, 57.60, 52.72, 48.77, 47.52, 44.52, 43.69, 36.93, 36.85, 29.11, 28.36, 27.85, 19.45, 13.22, 11.23, 10.93, 9.58.

Synthesis Method of Compound (36):

Weigh Compound 26 (50.0 mg) to dissolve it in 1 mL anhydrous methanol, add 0.27 mL piperidine and allow them to react overnight, then concentrate it before purify it with silica column chromatography to get 50 mg amine addition intermediate compound, then dissolve it in 10 mL methanol and add methane sulfonic acid in equivalent amount, then dry it through rotary evaporation to get Compound 36 (63 mg). ¹H NMR (CD₃OD, 400 MHz) δ 0.13-0.18 (m, 2H), 0.24-0.30 (m, 2H), 0.33-0.38 (m, 1H), 0.41-0.45 (m, 1H), 0.55-0.59 (m, 1H), 0.76-0.81 (m, 1H), 0.92 (d, J=6.5 Hz, 3H), 1.19-1.66 (m, 9H), 1.81-1.92 (m, 3H), 1.96-2.01 (m, 1H), 2.12-2.18 (m, 1H), 2.26-2.31 (m, 1H), 2.61 (s, 3H), 2.92-3.02 (m, 3H), 3.18-3.36 (m, 3H), 3.53 (t, J=13.6 Hz, 2H), 4.37 (t, J=10.1 Hz, 1H); ¹³C NMR (CD₃OD, 100 MHz) δ 9.4, 10.8, 11.1, 13.1, 19.3, 21.4, 27.7, 28.2, 28.9, 29.5, 32.4, 32.4, 36.7, 36.8, 39.7, 43.1, 47.7, 52.4, 54.2, 55.4, 56.6, 86.0, 178.

Synthesis Method of Compound (37):

Weigh Compound 26 (50.0 mg) to dissolve it in 1 mL anhydrous methanol, add 0.30 mL piperazine and allow them to react overnight, then concentrate it before purify it with silica column chromatography to get 51 mg amine addition intermediate compound, then dissolve it in 10 mL methanol and add fumaric acid in equivalent amount, then dry it through rotary evaporation to get Compound 37 (62 mg).

¹H NMR (CD₃OD, 400 MHz) δ 0.07-0.13 (m, 2H), 0.17-0.22 (m, 2H), 0.28-0.32 (m, 1H), 0.36-0.40 (m, 1H), 0.49-0.53 (m, 1H), 0.72-0.76 (m, 1H), 1.09-1.58 (m, 7H), 1.84-1.95 (m, 2H), 2.06-2.12 (m, 1H), 2.18-2.25 (m, 1H), 2.37-2.43 (m, 1H), 2.52-2.69 (m, 6H), 2.69 (s, 3H), 3.10 (brs, 3H), 3.16-3.17 (m, 1H), 4.19 (t, J=10.0 Hz, 1H), 6.56 (s, 2H)¹³C NMR (CD₃OD, 100 MHz) δ 9.5, 11.1, 11.2, 13.0, 19.4, 27.7, 28.3, 29.7, 36.8, 36.8, 43.4, 46.4, 47.9, 48.9, 51.6, 53.1, 54.5, 57.2, 85.6, 136, 170.6, 179.9.

Synthesis Method of Compound (38):

Dissolve Compound 26 (100 mg, 0.39 mmol) in anhydrous methanol (20 mL), then add morpholine (508 mg, 5.85 mmol) and stir overnight at room temperature. Separate and purify it through silica column chromatography to get the product (100 mg, 0.29 mmol), then dissolve the product in anhydrous methanol (5 mL), add methanesulfonic acid (27.8 mg, 0.29 mmol), then dry the methanol through rotary evaporation to get Compound 38 (127.8 mg).

¹H NMR (400 MHz, D₂O) δ 4.56 (t, J=10.1 Hz, 1H), 4.10 (s, 2H), 3.92 (m, J=17.5, 12.5 Hz, 2H), 3.67-3.46 (m, 3H), 3.39 (dd, J=13.8, 3.3 Hz, 1H), 3.35-3.25 (m, 2H), 3.12-3.01 (m, 1H), 2.77 (s, 3H), 2.34 (dt, J=15.8, 7.9 Hz, 2H), 2.05 (t, J=9.9 Hz, 1H), 1.93 (s, 1H), 1.76-1.44 (m, 5H), 1.43-1.33 (m, 1H), 1.34-1.22 (m, 1H), 0.88-0.74 (m, 1H), 0.65-0.52 (m, 1H), 0.52-0.18 (m, 6H); ¹³C NMR (100 MHz, D₂O) 178.38, 85.98, 63.53, 55.30, 50.93, 48.80, 47.00, 45.84, 41.70, 38.45, 35.16, 34.68, 27.34, 26.77, 26.31, 17.94, 11.76, 9.99, 9.71, 8.11.

Synthesis Method of Compound (39):

Dissolve Compound 26 (50 mg, 0.195 mmol) in anhydrous methanol (5 mL), then add pyrrolidine (208 mg, 2.93 mmol) and stir overnight at room temperature. Separate and purify it through silica column chromatography to get the product (52 mg, 0.16 mmol), dissolve the product in anhydrous methanol (5 mL), add methanesulfonic acid (15.2 mg, 0.16 mmol), then dry the methanol through rotary evaporation to get Compound 39 (57.2 mg).

¹H NMR (400 MHz, D₂O) δ 4.44 (t, J=10.0 Hz, 1H), 3.79-3.58 (m, 2H), 3.50 (dd, J=13.4, 9.5 Hz, 1H), 3.35 (dd, J=13.5, 3.6 Hz, 1H), 3.21-3.03 (m, 2H), 2.90 (dd, J=5.9, 3.2 Hz, 1H), 2.73 (s, 3H), 2.33 (d, J=8.5 Hz, 1H), 2.24-2.08 (m, 3H), 2.06-1.95 (m, 3H), 1.92 (s, 1H), 1.52 (dt, J=24.8, 8.8 Hz, 5H), 1.33-1.15 (m, 2H), 0.87-0.71 (m, 1H), 0.65-0.53 (m, 1H), 0.46-0.08 (m, 6H); ¹³C NMR (100 MHz, D₂O) δ 178.08, 85.50, 55.92, 54.06, 52.97, 50.74, 46.95, 45.81, 43.22, 38.44, 35.58, 35.18, 27.47, 26.99, 26.50, 22.66, 22.54, 18.10, 12.03, 10.04, 9.54, 8.43.

Synthesis Method of Compound (40):

Compound 26 (100 mg, 0.39 mmol) in anhydrous methanol (2 mL), then add N-methylethanolamine (438 mg, 5.85 mmol) and stir overnight at room temperature. Separate and purify through silica column chromatography to get the product (100 mg, 0.30 mmol), dissolve the product in CH₂Cl₂ (5 mL), add methanesulfonic acid (28.8 mg, 0.30 mmol), then dry the CH₂Cl₂ through rotary evaporation to get Compound 40 (128.8 mg).

¹H NMR (400 MHz, CDCl₃) δ 4.36 (t, J=9.9 Hz, 1H), 3.92 (s, 2H), 3.65-3.43 (m, 2H), 3.34 (s, 2H), 3.01 (s, 3H), 2.98-2.83 (m, 1H), 2.71 (s, J=2.8 Hz, 3H), 2.37-2.22 (m, 1H), 2.19-2.10 (m, 2H), 2.05-1.88 (m, 2H), 1.57 (m, J=29.9, 18.2 Hz, 5H), 1.31 (d, J=10.9 Hz, 1H), 1.21 (s, 1H), 0.78 (m, 1H), 0.59 (m, 1H), 0.54-0.06 (m, 6H).

Synthesis Method of Compound (41):

Dissolve Compound 26 (50-mg, 0.195 mmol) in anhydrous methanol (2 mL), then add N-Methylbutylamine (254 mg, 2.93 mmol) and stir overnight at room temperature. Separate and purify it through silica column chromatography to get the amine addition intermediate product (50 mg, 0.14 mmol), dissolve the product in CH₂Cl₂ (5 mL), add methanesulfonic acid (13.9 mg, 0.14 mmol), then dry the CH₂Cl₂ through rotary evaporation to get Compound 41 (63.9 mg).

¹H NMR (400 MHz, D₂O) δ 4.60 (s, 1H), 3.59-3.07 (m, 4H), 3.06-2.96 (m, 1H), 2.90 (s, 3H), 2.77 (s, 3H), 2.32 (dd, J=18.0, 8.9 Hz, 2H), 2.07-1.97 (m, 1H), 1.94-1.81 (m, 1H), 1.76-1.62 (m, 3H), 1.61-1.51 (m, 2H), 1.48 (d, J=8.1 Hz, 1H), 1.45-1.24 (m, 5H), 0.91 (t, J=7.4 Hz, 3H), 0.83-0.76 (m, 1H), 0.57-0.49 (m, 1H), 0.45 (ddd, J=17.8, 8.7, 4.7 Hz, 2H), 0.38-0.24 (m, 3H), 0.23-0.17 (m, 1H).

Synthesis Method of Compound 42-45:

Add trimethylsilyl azide (575 mg, 5.0 mmol) and acetic acid (300 mg, 5.0 mmol) in 50 mL round bottom flask, agitate 20 minutes at room temperature and then add Compound 26 (258 mg, 1.0 mmol) and catalytic amount of thiethylamine (20.2 mg, 0.2 mmol) in the reaction solution, heat it to 60° C. and stir it until the reaction is completed (TLC test). Pour the reaction mixture into appropriate amount ice water and extract it with ethyl acetate (50 mL×3), then wash separately with saturated NaHCO₃ solution (20 mL×3) and saturated saline solution (20 mL×3) in turn, then dry it with anhydrous sodium sulfate. Filter it by suction before concentrate it to get the azidation intermediate.

Take the azidation intermediate (0.25 mmol), sodium ascorbate (10 mg, 0.05 mmol) and copper sulfate pentahydrate (12 mg, 0.05 mmol) into a reaction flask dried in advance, then vacuumize it and charge nitrogen gas before seal the mouth. Then add 5 mL solvent mixture (tert-butyl alcohol: water=1:1) and 5-hexynyl-1-ol (49 mg, 0.5 mmol) and stir it at room temperature until the raw materials are reacted completely (TCL test). Pour the reaction mixture into appropriate amount of ice water and then extract with ethyl acetate (10 mL×3), then wash it with saturated saline solution three times, then dry it with anhydrous sodium sulfate, concentrate it at reduced pressure before purify it through silica gel column chromatography to get Compound 42 (71 mg).

¹H NMR (400 MHz, CDCl₃) δ 7.40 (s, 1H), 4.73-4.58 (m, 2H), 4.23 (t, J=10.0 Hz, 1H), 3.65 (t, J=6.3 Hz, 2H), 2.73 (t, J=7.4 Hz, 2H), 2.63 (dt, J=11.7, 4.2 Hz, 1H), 2.21 (dd, J=18.0, 9.0 Hz, 1H), 1.96-1.89 (m, 1H), 1.88-1.80 (m, 2H), 1.79-1.69 (m, 3H), 1.59 (dt, J=16.7, 7.6 Hz, 4H), 1.52-1.44 (m, 2H), 1.38-1.29 (m, 2H), 1.27-1.19 (m, 1H), 0.81 (dd, J=9.2, 4.8 Hz, 1H), 0.65-0.54 (m, 1H), 0.47-0.40 (m, 1H), 0.40-0.35 (m, 1H), 0.34-0.27 (m, 1H), 0.23 (m, 3H) ¹³C NMR (CDCl₃, 100 MHz) 176.1, 149.0, 122.3, 84.9, 62.4, 52.0, 48.6, 47.9, 47.5, 44.6, 36.0, 35.5, 32.4, 28.6, 27.6, 27.0, 25.9, 25.6, 18.6, 12.8, 11.1, 10.9, 9.1.

Employ the above-mentioned method to prepare Compound 43 (70 mg).

¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.81 (d, J=7.6 Hz, 2H), 7.39 (t, J=7.4 Hz, 2H), 7.29 (dd, J=14.9, 7.7 Hz, 1H), 4.79-4.65 (m, 2H), 4.20 (t, J=9.9 Hz, 1H), 2.68 (dt, J=8.7, 4.1 Hz, 1H), 2.17 (dd, J=17.9, 8.9 Hz, 1H), 2.07-1.92 (m, 1H), 1.84 (d, J=6.1 Hz, 1H), 1.74 (t, J=9.8 Hz, 1H), 1.63-1.49 (m, 2H), 1.42 (dd, J=13.1, 7.5 Hz, 2H), 1.30 (dt, J=20.0, 9.9 Hz, 2H), 1.24-1.15 (m, 1H), 0.79 (dd, J=17.1, 12.5 Hz, 1H), 0.61-0.51 (m, 1H), 0.37 (dd, J=20.4, 4.1 Hz, 2H), 0.29-0.13 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 175.54, 148.13, 130.37, 128.88, 128.29, 125.73, 120.84, 84.53, 51.46, 48.24, 47.47, 47.20, 44.21, 35.62, 35.21, 28.27, 27.24, 26.61, 18.29, 12.51, 10.69, 10.42, 8.70.

Employ the above-mentioned method to prepare Compound 44 (63 mg).

¹H NMR (400 MHz, CDCl₃) δ 8.21 (s, 1H), 4.81-4.68 (m, 2H), 4.28 (dd, J=19.8, 9.6 Hz, 1H), 3.95 (s, 3H), 2.76-2.65 (m, 1H), 2.20 (q, J=9.1 Hz, 1H), 2.04-1.85 (m, 2H), 1.74 (t, J=9.9 Hz, 1H), 1.65 (dd, J=19.0, 10.4 Hz, 1H), 1.60-1.43 (m, 3H), 1.42-1.32 (m, 2H), 1.32-1.19 (m, 1H), 0.81 (dt, J=9.5, 4.7 Hz, 1H), 0.59 (dt, J=9.2, 4.5 Hz, 1H), 0.49-0.36 (m, 2H), 0.36-0.29 (m, 1H), 0.30-0.20 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 175.09, 160.87, 140.15, 128.87, 84.49, 52.19, 51.58, 48.00, 47.55, 47.51, 44.20, 35.51, 34.96, 28.18, 27.18, 26.54, 18.23, 12.42, 10.76, 10.53, 8.64.

Employ the above-mentioned method to prepare Compound 45 (65 mg).

¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J=33.3 Hz, 1H), 5.07 (d, J=4.9 Hz, 1H), 4.78-4.60 (m, 2H), 4.26 (t, J=10.0 Hz, 1H), 2.68 (dt, J=9.5, 4.4 Hz, 1H), 2.23 (dd, J=17.7, 8.7 Hz, 1H), 2.03-1.92 (m, 1H), 1.89-1.73 (m, 2H), 1.69-1.62 (m, 1H), 1.62-1.54 (m, 4H), 1.47 (t, J=12.5 Hz, 2H), 1.35 (dd, J=20.3, 10.3 Hz, 2H), 1.30-1.18 (m, 2H), 0.87-0.77 (m, 1H), 0.67-0.57 (m, 1H), 0.49-0.36 (m, 2H), 0.36-0.29 (m, 1H), 0.25 (m, 3H).

Synthesis Method of Compound (46):

Take Compound 26 (167 mg) and deuterated dimethylamine hydrochloride (530 mg) to dissolve in 15 mL CH₂Cl₂, then add 1.8 g K₂CO₃ and reflux 24 hours, then filter it before dry it through rotary evaporation, then purify it with silica column chromatography to get the dimethylamino intermediate (150 mg), weigh 49 mg intermediate to dissolve it in 10 mL methanol and then add 18.7 mg fumaric acid to stir 10 minutes, then dry it through rotary evaporation to get Compound 46 (67 mg).

¹H NMR (400 MHz, MeOD) δ 6.70 (s, 2H), 4.46 (dd, J=18.9, 8.7 Hz, 1H), 3.46 (dd, J=13.4, 6.3 Hz, 1H), 3.35-3.28 (m, 1H), 2.95 (d, J=14.0 Hz, 6H), 2.38 (dd, J=17.4, 9.1 Hz, 1H), 2.27-2.19 (m, 1H), 2.11-2.03 (m, 1H), 2.01-1.92 (m, 1H), 1.67 (ddd, J=18.7, 11.2, 5.0 Hz, 2H), 1.60-1.48 (m, 3H), 1.45-1.27 (m, 2H), 0.88 (dt, J=9.6, 4.8 Hz, 1H), 0.66 (ddd, J=9.3, 5.4, 3.8 Hz, 1H), 0.56-0.50 (m, 1H), 0.45 (dt, J=9.3, 4.7 Hz, 1H), 0.36 (dt, J=11.9, 4.7 Hz, 2H), 0.29-0.20 (m, 2H); ¹³C NMR (101 MHz, MeOD) δ 178.31, 171.09, 136.26, 86.31, 57.22, 52.69, 48.74, 47.41, 44.23, 36.90, 36.82, 30.84, 29.03, 28.35, 27.83, 19.43, 13.21, 11.20, 10.90, 9.56.

Synthesis Method of Compound (47):

Dissolve parthenolide (566.2 mg, 1.99 mmol) in methanol and add p-toluenesulfonic acid (687.5 mg, 4.0 mmol). Place the reaction system at room temperature and stir it overnight. Neutralize the reaction mixture with Na₂HPO₄ (568 mg, 4.0 mmol), then extract it with CH₂Cl₂, collect the organic layer and dry it with Na₂SO₄, then filter it and evaporate the organic solvent at reduced pressure with rotary evaporator, purify the remaining product with silica gel column to get Compound 47. ¹H NMR (CDCl₃, 400 MHz) δ 6.12 (d, J=2.8 Hz, 1H), 5.44 (s, 1H), 4.13 (t, J=9.6 Hz, 1H), 3.12 (d, J=2.8 Hz, 3H), 2.79 (t, J=11.8 Hz, 2H), 2.26 (t, J=9.6 Hz, 1H), 2.11-2.08 (m, 1H), 1.98-1.62 (m, 6H), 1.52-1.45 (m, 1H), 1.31-1.37 (m, 4H), 1.09 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.5, 138.9, 119.8, 82.5, 80.3, 77.9, 55.3, 48.1, 46.4, 45.7, 35.3, 38.7, 25.2, 24.1, 22.5, 14.0.

Synthesis Method of Compound (48 and 49):

Add amberlyst 15 (12.88 g) into parthenolide (1.03 g, 4.1 mmol) solution and the solution of acetone: water (95:5), place the reaction system to react at room temperature and monitor the reaction with TLC until the raw materials disappear. After the reaction is completed, remove the solvent through rotary evaporation, dissolve the remaining substances in CH₂Cl₂, and dry with Na₂SO₄. Filter the product and remove the solvent through rotary evaporation, then purify it through silica gel column to get the products 48 and 49.

Compound 48: ¹H NMR (CDCl₃, 400 MHz) δ 6.12 (d, J=3.2 Hz, 1H), 5.44 (d, J=3.2 Hz, 1H), 4.92 (s, 1H), 4.88 (s, 1H), 4.03-3.94 (m, 1H), 2.93 (dd, J=11.6, 8.8 Hz, 1H), 2.71-2.65 (m, 1H), 2.61-2.56 (m, 1H), 2.29 (t, J=12 Hz, 1H), 2.22-2.16 (m, 1H), 1.85-1.74 (m, 3H), 1.72-1.69 (m, 31H), 1.34-1.26 (m, 3H), 1.23 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 169.6, 147.8, 138.5, 120.5, 112.4, 83.8, 79.5, 55.4, 47.0, 43.7, 40.0, 38.9, 31.2, 25.9, 23.6.

Compound 49: ¹H NMR (CDCl₃, 400 MHz) δ 6.24 (d, J=3.6 Hz, 1H), 5.56 (d, J=3.2 Hz, 1H), 4.26 (s, 1H), 9.6 (s, 1H), 2.75-2.62 (m, 1H), 2.40 (dd, J=11.6, 12.4 Hz, 1H), 2.20-2.14 (m, 1H), 2.08-2.56 (m, 1H), 2.03 (t, J=12 Hz, 1H), 1.76-1.60 (m, 1H), 1.52-1.45 (m, 3H), 1.36-1.69 (m, 3H), 1.28-1.26 (m, 3H), 1.25 (s, 3H); ¹³C NMR (CDCl₁, 400 MHz) δ 169.6, 138.4, 120.4, 82.7, 80.0, 74.7, 55.2, 49.6, 47.1, 39.3, 25.2, 24.9, 24.1, 23.4, 20.6.

Preparation of Compound 50:

Dissolve Martin's sulfurane (382 mg, 0.57 mmol) in 2 mL CH₂Cl₂, under the protection of Ar, slowly drip 4 mL CH₂Cl₂ solution of Compound 24. The reaction mixture solution changes gradually to yellow color, then stir it 24 hours, after the reactive raw materials disappear completely, remove the solvent through rotary evaporation at reduced pressure to get yellow oily substance, and then purify the crude product with silica gel column to get Compound 50. ¹H NMR (CDCl₃, 400 MHz) δ 6.14 (d, J=3.2 Hz, 1H), 5.57 (s, 1H), 5.41 (d, J=3.2 Hz, 1H), 4.00 (t, J=10.4 Hz, 1H), 2.93 (br.d, J=10.8 Hz, 1H), 2.77 (br.d, J=17.6 Hz, 1H), 2.27-2.12 (m, 3H), 2.03 (m, 1H), 1.9 7 (br s, 3H), 1.84 (br.d, J=14.0 Hz, 1H), 1.48 (m, 1H), 1.35 (s, 3H); ¹³C NMR (CDCl₃, 400 MHz) δ 170.6, 140.7, 139.2, 125.0, 118.4, 83.0, 72.6, 62.8, 52.9, 51.2, 39.8, 33.6, 22.9, 21.6, 18.4.

Embodiment 2 Test of Anti-Rheumatoid Arthritis Activity of Compound 1-50

In the field of anti-rheumatoid arthritis drugs, there are many literatures reporting the effects of drug ingredients on synoviocyte to secrete TNF-α, PGE2 and IL-1β and using the data from animal test to investigate the therapeutic effect of drug on RA. These studies include [1] Dahong Ju, Hlongwei Jia and Hao Wu, et al. Effects of Cervus and Cucumis Polypeptide Injection on Activity of Antibodies TNF-α, IL-6 and C II of Immune Arthritis Rat Serum Induced by C II, China Journal of Basic Medicine in Traditional Chinese Medicine, 2003, 9 (11); 17. [2] JinHua He, Qinghua Liang, Huasheng Zhang, et al. Effects of Bizhongxiao Decoction on Plasma TNF-α of Experimental Arthritis Rats, Bulletin of Hunan Medical University, 2002, 27(5): 524. [3] Qingchun Huang, Shengpeng Zhang, Qiuying Xu. Effects of Compound Danshen on Synoviocyte's Secretion and Tumor Necrosis Factor of Rat Model Induced by Type II Collagen, 2001, 5 (10): 54-55. [4] Zhigang Zheng, Cytokine and Its Test Method and Clinical Significance, Shaanxi J Med Lab Sci, 2001, 16(2): 59. [5] Jun Zhou, Suping Fang, Yun Qi, et al. Effects of Kakkonto on Inflammatory Mediator in Joint Fluid of Adjuvant Induced Arthritis Rats, 2001, 7(3): 29. [6] Ji Ma, Bingjiu Lu, Xiaoming Zhu, et al. Study on Pharmacodynamics of Tongbi Keli to Treat Rheumatoid Arthritis, 2001, 19(6): 734. [7]Jiang Zhu, Wenli Xie, Yuzhnag Jin, et al. Effects of Gardenia on Serum IL-1β and TNF-α of Rheumatoid Arthritis Rats, Chinese Traditional Patent Medicine, 2005, 27(7): 801. [8]Qingchun Huang, Shengpeng Zhang, Weiyi Huang, et al. Effects of Compound Danshen Injection on Expression of IL-1βmRNA of CIA Rat Synoviocyte, Journal of Anhui Traditional Chinese Medical College, 2002, 21(5): 39-41.

Take Compound 1-50 prepared as per the method according to the present invention and employ the method provided in Reference [3] to prepare model, group drugs and prepare culture supernatant of rat synoviocyte.

Employ the method provided in Reference [3] to investigate the effects of the test compounds on the synoviocyte to secrete TNF-α and PGE2. Employ the method provided in Reference [8] to investigate the effects of the test compounds on the synoviocyte to secrete IL-1β.

The experimental data of the test compound 1-50 at a dose of 30 mg/kg.2d as well as the normal control and NaCl group are as follows:

TABLE 1 Content of TNF-α in culture supernatant of synoviocyte (x ± s, ng/mL) Group TNF-α Normal control 0.38 ± 0.027 NaCl 0.74 ± 0.098 Compound 1 0.41 ± 0.076 Compound 2 0.45 ± 0.052 Compound 3 0.55 ± 0.042 Compound 4 0.56 ± 0.064 Compound 5 0.49 ± 0.056 Compound 6 0.61 ± 0.072 Compound 7 0.56 ± 0.044 Compound 8 0.58 ± 0.053 Compound 9 0.61 ± 0.065 Compound 10 0.54 ± 0.055 Compound 11 0.49 ± 0.076 Compound 12 0.66 ± 0.043 Compound 13 0.62 ± 0.056 Compound 14 0.48 ± 0.055 Compound 15 0.54 ± 0.045 Compound 16 0.57 ± 0.073 Compound 17 0.66 ± 0.077 Compound 18 0.64 ± 0.072 Compound 19 0.62 ± 0.056 Compound 20 0.58 ± 0.045 Compound 21 0.56 ± 0.034 Compound 22 0.61 ± 0.082 Compound 23 0.63 ± 0.063 Compound 24 0.54 ± 0.057 Compound 25 0.58 ± 0.056 Compound 26 0.59 ± 0.051 Compound 27 0.54 ± 0.066 Compound 28 0.47 ± 0.056 Compound 29 0.66 ± 0.046 Compound 30 0.65 ± 0.057 Compound 31 0.62 ± 0.056 Compound 32 0.64 ± 0.044 Compound 33 0.63 ± 0.054 Compound 34 0.54 ± 0.067 Compound 35 0.57 ± 0.057 Compound 36 0.66 ± 0.045 Compound 37 0.59 ± 0.035 Compound 38 0.67 ± 0.045 Compound 39 0.52 ± 0.056 Compound 40 0.48 ± 0.078 Compound 41 0.45 ± 0.056 Compound 42 0.58 ± 0.055 Compound 43 0.55 ± 0.045 Compound 44 0.54 ± 0.071 Compound 45 0.49 ± 0.056 Compound 46 0.56 ± 0.034 Compound 47 0.64 ± 0.062 Compound 48 0.62 ± 0.054 Compound 49 0.65 ± 0.046 Compound 50 0.52 ± 0.064

TABLE 2 Content of IL-1β in culture supernatant of synoviocyte (x ± s, ng/mL) Group IL-1β Normal control 0.16 ± 0.034 NaCl 0.49 ± 0.136 Compound 1 0.26 ± 0.042 Compound 2 0.28 ± 0.045 Compound 3 0.36 ± 0.039 Compound 4 0.42 ± 0.064 Compound 5 0.38 ± 0.062 Compound 6 0.36 ± 0.054 Compound 7 0.39 ± 0.058 Compound 8 0.41 ± 0.051 Compound 9 0.45 ± 0.064 Compound 10 0.42 ± 0.069 Compound 11 0.39 ± 0.081 Compound 12 0.38 ± 0.069 Compound 13 0.37 ± 0.062 Compound 14 0.36 ± 0.054 Compound 15 0.41 ± 0.051 Compound 16 0.34 ± 0.039 Compound 17 0.37 ± 0.065 Compound 18 0.39 ± 0.029 Compound 19 0.42 ± 0.091 Compound 20 0.34 ± 0.056 Compound 21 0.36 ± 0.057 Compound 22 0.34 ± 0.038 Compound 23 0.36 ± 0.065 Compound 24 0.37 ± 0.051 Compound 25 0.39 ± 0.067 Compound 26 0.42 ± 0.052 Compound 27 0.41 ± 0.047 Compound 28 0.31 ± 0.067 Compound 29 0.34 ± 0.039 Compound 30 0.38 ± 0.049 Compound 31 0.39 ± 0.051 Compound 32 0.37 ± 0.047 Compound 33 0.41 ± 0.052 Compound 34 0.35 ± 0.059 Compound 35 0.41 ± 0.056 Compound 36 0.29 ± 0.064 Compound 37 0.31 ± 0.037 Compound 38 0.35 ± 0.062 Compound 39 0.34 ± 0.095 Compound 40 0.31 ± 0.061 Compound 41 0.41 ± 0.054 Compound 42 0.36 ± 0.059 Compound 43 0.43 ± 0.062 Compound 44 0.35 ± 0.069 Compound 45 0.38 ± 0.039 Compound 46 0.36 ± 0.067 Compound 47 0.34 ± 0.058 Compound 48 0.38 ± 0.046 Compound 49 0.39 ± 0.075 Compound 50 0.34 ± 0.061

TABLE 3 Content of PGE2 in culture supernatant of synoviocyte (x ± s, ng/mL) Group IL-1β Normal control  8.34 ± 1.29 NaCl  32.44 ± 10.32 Compound 1 15.24 ± 1.77 Compound 2 18.58 ± 0.98 Compound 3 26.96 ± 1.59 Compound 4 24.49 ± 2.67 Compound 5 25.67 ± 4.23 Compound 6 26.75 ± 1.69 Compound 7 22.82 ± 2.67 Compound 8 23.69 ± 1.25 Compound 9 27.92 ± 2.67 Compound 10 25.67 ± 7.12 Compound 11 26.38 ± 3.15 Compound 12 24.59 ± 2.35 Compound 13 25.61 ± 0.98 Compound 14 26.44 ± 1.26 Compound 15 24.39 ± 2.38 Compound 16 27.61 ± 4.21 Compound 17 28.95 ± 3.24 Compound 18 20.62 ± 2.47 Compound 19 26.45 ± 5.21 Compound 20 27.38 ± 1.39 Compound 21 19.59 ± 3.25 Compound 22 24.69 ± 4.19 Compound 23 21.71 ± 2.32 Compound 24 23.63 ± 1.35 Compound 25 26.48 ± 2.57 Compound 26 25.61 ± 5.41 Compound 27 24.75 ± 2.66 Compound 28 18.92 ± 1.98 Compound 29 27.64 ± 2.37 Compound 30 25.37 ± 4.21 Compound 31 24.41 ± 1.65 Compound 32 22.75 ± 4.25 Compound 33 26.64 ± 2.67 Compound 34 24.61 ± 3.24 Compound 35 21.54 ± 1.32 Compound 36 25.64 ± 2.14 Compound 37 27.94 ± 2.69 Compound 38 19.67 ± 3.14 Compound 39 28.35 ± 2.15 Compound 40 25.34 ± 3.57 Compound 41 26.63 ± 1.59 Compound 42 22.58 ± 4.21 Compound 43 24.64 ± 3.95 Compound 44 22.14 ± 2.87 Compound 45 23.26 ± 3.49 Compound 46 24.74 ± 2.64 Compound 47 27.95 ± 3.67 Compound 48 26.65 ± 2.45 Compound 49 24.25 ± 1.94 Compound 50 19.83 ± 1.78

The present invention selects the rat as the animal model for human RA and employs the method of primary culture of synoviocyte to observe the effects of Compounds 1-50 on the synoviocyte to secrete TNF-α, PGE2 and IL-1β. The result indicates that Compounds 1-50 all can obviously reduce the content of TNF-α, PGE2 and IL-1β of both large dose group and small dose group, to realize the functions of alleviating damages to bone and cartilage as well as restoring the action function of joint and realize the effect of RA treatment.

Embodiment 3 Test of Compound Activity to Inhibit Cancer Stem Cell

Take fresh or cryopreserved clinical specimen (acute myelogenous leukemia (AML, marker is CD34⁺/CD38⁺), chronic myelogenous leukemia (CML, Ph+/CD34+/CXCR4+), chronic lymphocytic leukemia (CLL,CD133+/CD19−/CD38−), skin cancer (CD34+), breast cancer (CD44+/CD24−/ESA+), ovarian cancer (CD44+/CD117+), brain tumor (CD133+) prostate cancer (CD44+/CD24−), head-neck squamous cell carcinoma (CD44+), laryngeal cancer (CD133+), pancreatic cancer (ESA+/CD44+/CD24+), retinoblastoma (ABCG2/ALDH1), Children hepatoblastoma (CD34+/THY1+/c-kit+), liver cancer (CD133+), malignant melanoma (CD133+), colorectal cancer (EpCAM^(high)/CD44+), colon adenocarcinoma (CD44^(high)), glioma (ABCG-2/BCRP1), gastrointestinal tumor (ABCG-2/BCRP1), nasopharynx cancer (ABCG2), brain glioma (Dlk-1/Pref-1), gastric cancer (CD45+), lung adenocarcinoma (Sca-1/CD45-/Pecam-/CD34+), lung cancer (CD133+CD34+CD44+)) of patient. Take the acute myelogenous leukemia as the example, conduct density gradient centrifugation with Ficoll and take out the middle mononuclear cells, re-suspend it with serum-free IMDM after centrifuged. Adjust the concentration of cells into 1×10⁶/mL and lay 24-well plate with 1 mL in each well, and then treat 18 hours with the compound to select with corresponding concentration. Collect the cells and centrifuge them at 1500 rps for 8 minutes, re-suspend the precipitation with 100 ml, mark the antibodies related to leukemia stem cell, avoid light to incubate 30 minutes at room temperature and then centrifuge it at 1500 rps, then wash away the unbound antibody CD34⁺CD38⁺. Re-suspend it with 100 μl 1× Binding Buffer and add respectively 5 μl Annexin V-FITC and PI, then avoid light to incubate 15 minutes before add 200 μl 1× Binding Buffer, then use flow cytometry to examine the marked apoptosis within one hour.

TABLE 4 Survival rate (%) of cancer cells, cancer stem cells and normal cells after test compound is added 10.0 μM 20.0 μM All cells All cells (Stem (Stem cells and cells and Stem ordinary Stem ordinary Compound Cells cells cells) cells cells) Compound 1 AML 34 55 24 45 CML 55 65 26 39 CLL 44 55 32 46 Skin cancer 57 59 23 28 Breast cancer 65 69 42 55 Ovarian cancer 67 78 45 59 Brain tumor 78 88 69 72 Prostate cancer 34 46 21 26 Head and neck 60 67 37 48 squamous cell carcinomas Laryngeal cancer 65 75 54 64 Pancreatic cancer 54 64 36 48 Retinoblastoma 55 64 34 54 Children 46 54 29 37 hepatoblastoma Liver cancer 55 68 36 48 Malignant melanoma 72 85 56 69 Colorectal cancer 65 78 45 67 Colon 43 56 24 39 adenocarcinoma Glioma 77 87 66 72 Gastrointestinal 56 62 41 51 tumor Nasopharynx cancer 25 34 17 28 Brain glioma 65 69 37 47 Gastric cancer 45 56 27 37 Lung 36 47 24 34 adenocarcinoma Lung cancer 45 53 19 26 Normal cells 88 91 91 93 Compound 2 AML 38 54 34 46 CML 41 49 36 41 CLL 48 57 37 49 Skin cancer 36 42 29 37 Breast cancer 44 57 37 51 Ovarian cancer 37 48 35 41 Brain tumor 56 64 44 59 Prostate cancer 41 45 31 42 Head and neck 54 67 37 48 squamous cell carcinomas Laryngeal cancer 55 75 54 64 Pancreatic cancer 47 69 59 64 Retinoblastoma 52 62 44 49 Children 57 53 37 41 hepatoblastoma Liver cancer 64 62 41 58 Malignant melanoma 71 75 66 69 Colorectal cancer 56 68 45 57 Colon 48 56 44 51 adenocarcinoma Glioma 67 77 66 73 Gastrointestinal 46 52 41 47 tumor Nasopharynx cancer 37 44 27 29 Brain glioma 62 68 47 53 Gastric cancer 41 46 37 47 Lung 64 73 54 64 adenocarcinoma Lung cancer 41 52 34 46 Normal cells 91 92 89 91 Compound 5 AML 39 47 34 41 CML 45 55 36 42 CLL 37 52 34 44 Skin cancer 55 61 43 49 Breast cancer 55 64 43 51 Ovarian cancer 57 68 35 45 Brain tumor 77 87 66 72 Prostate cancer 56 62 41 51 Head and neck 45 54 37 48 squamous cell carcinomas Laryngeal cancer 65 69 37 47 Pancreatic cancer 45 56 27 37 Retinoblastoma 62 68 47 56 Children 52 56 47 51 hepatoblastoma Liver cancer 49 57 42 52 Malignant melanoma 55 58 45 49 Colorectal cancer 65 78 45 67 Colon 43 56 24 39 adenocarcinoma Glioma 77 87 66 72 Gastrointestinal 56 62 41 51 tumor Nasopharynx cancer 25 34 17 28 Brain glioma 65 69 37 47 Gastric cancer 45 56 27 37 Lung 36 47 24 34 adenocarcinoma Lung cancer 45 53 19 26 Normal cells 95 96 93 94 Compound 8 AML 34 55 24 45 CML 55 65 26 39 CLL 44 55 32 46 Skin cancer 57 59 23 28 Breast cancer 65 69 42 55 Ovarian cancer 67 78 45 59 Brain tumor 78 88 69 72 Prostate cancer 34 46 21 26 Head and neck 60 67 37 48 squamous cell carcinomas Laryngeal cancer 52 58 39 47 Pancreatic cancer 62 75 56 68 Retinoblastoma 62 68 45 57 Children 48 61 34 43 hepatoblastoma Liver cancer 52 58 39 47 Malignant melanoma 62 75 56 68 Colorectal cancer 57 59 23 28 Colon 65 69 42 55 adenocarcinoma Glioma 67 78 45 59 Gastrointestinal 78 88 69 72 tumor Nasopharynx cancer 34 46 21 26 Brain glioma 60 67 37 48 Gastric cancer 65 75 54 64 Lung 62 68 47 56 adenocarcinoma Lung cancer 52 56 47 51 Normal cells 95 96 89 94 Compound 11 AML 55 58 45 49 CML 65 71 49 59 CLL 45 55 34 43 Skin cancer 55 65 26 39 Breast cancer 44 55 32 46 Ovarian cancer 57 59 23 28 Brain tumor 45 69 42 55 Prostate cancer 45 67 37 56 Head and neck 65 69 47 59 squamous cell carcinomas Laryngeal cancer 61 72 53 62 Pancreatic cancer 47 58 37 46 Retinoblastoma 52 61 44 56 Children 45 53 39 47 hepatoblastoma Liver cancer 52 58 39 47 Malignant melanoma 62 75 56 68 Colorectal cancer 62 68 45 57 Colon 48 61 34 43 adenocarcinoma Glioma 67 77 56 62 Gastrointestinal 49 57 40 52 tumor Nasopharynx cancer 45 54 34 48 Brain glioma 62 68 47 56 Gastric cancer 52 56 47 51 Lung 49 57 42 52 adenocarcinoma Lung cancer 55 58 45 49 Normal cells 92 96 90 93 Compound 13 AML 45 55 34 43 CML 55 65 26 39 CLL 44 55 32 46 Skin cancer 57 59 23 28 Breast cancer 45 69 42 55 Ovarian cancer 67 78 45 59 Brain tumor 78 88 69 72 Prostate cancer 34 46 21 26 Head and neck 60 67 37 48 squamous cell carcinomas Laryngeal cancer 65 75 54 64 Pancreatic cancer 54 64 46 52 Retinoblastoma 35 44 24 44 Children 46 54 29 37 hepatoblastoma Liver cancer 55 68 36 48 Malignant melanoma 72 85 56 69 Colorectal cancer 65 78 45 67 Colon 43 56 24 39 adenocarcinoma Glioma 77 87 66 72 Gastrointestinal 56 62 41 51 tumor Nasopharynx cancer 25 34 17 28 Brain glioma 65 69 37 47 Gastric cancer 41 55 37 47 Lung 57 68 44 54 adenocarcinoma Lung cancer 62 73 45 61 Normal cells 92 95 87 93 Compound 14 AML 42 67 37 56 CML 65 69 47 59 CLL 61 72 53 62 Skin cancer 47 58 37 46 Breast cancer 52 61 44 56 Ovarian cancer 45 53 39 47 Brain tumor 55 64 43 51 Prostate cancer 57 68 35 45 Head and neck 76 87 66 72 squamous cell carcinomas Laryngeal cancer 56 62 41 51 Pancreatic cancer 49 57 40 52 Retinoblastoma 45 54 34 49 Children 63 68 47 56 hepatoblastoma Liver cancer 52 56 46 51 Malignant melanoma 57 69 35 45 Colorectal cancer 62 68 45 57 Colon 48 61 34 43 adenocarcinoma Glioma 67 77 56 63 Gastrointestinal 55 65 26 39 tumor Nasopharynx cancer 44 54 32 46 Brain glioma 57 59 23 28 Gastric cancer 45 69 42 55 Lung 47 69 59 64 adenocarcinoma Lung cancer 52 62 44 49 Normal cells 93 94 91 93 Compound 21 AML 66 75 47 56 CML 75 82 56 69 CLL 51 63 48 62 Skin cancer 56 64 47 57 Breast cancer 62 72 55 66 Ovarian cancer 56 64 49 57 Brain tumor 65 75 54 62 Prostate cancer 68 77 57 65 Head and neck 75 86 66 82 squamous cell carcinomas Laryngeal cancer 66 73 52 61 Pancreatic cancer 57 66 50 62 Retinoblastoma 56 65 47 59 Children 74 81 57 66 hepatoblastoma Liver cancer 64 77 55 61 Malignant melanoma 59 69 45 56 Colorectal cancer 73 78 58 67 Colon 58 71 44 56 adenocarcinoma Glioma 78 87 67 78 Gastrointestinal 64 75 46 58 tumor Nasopharynx cancer 55 65 42 56 Brain glioma 68 79 53 68 Gastric cancer 56 67 45 55 Lung 58 67 49 64 adenocarcinoma Lung cancer 63 74 54 68 Normal cells 94 95 92 94 Compound 23 AML 85 92 72 84 CML 87 91 71 79 CLL 86 95 74 85 Skin cancer 85 95 75 87 Breast cancer 84 89 74 86 Ovarian cancer 87 91 75 84 Brain tumor 85 89 73 85 Prostate cancer 85 92 77 89 Head and neck 84 91 78 88 squamous cell carcinomas Laryngeal cancer 79 88 73 82 Pancreatic cancer 87 90 77 86 Retinoblastoma 82 91 74 85 Children 85 93 79 86 hepatoblastoma Liver cancer 82 88 79 87 Malignant melanoma 82 89 76 86 Colorectal cancer 79 88 72 81 Colon 88 91 81 89 adenocarcinoma Glioma 87 94 76 87 Gastrointestinal 91 94 82 88 tumor Nasopharynx cancer 85 94 74 81 Brain glioma 84 88 76 85 Gastric cancer 82 86 77 84 Lung 85 87 82 87 adenocarcinoma Lung cancer 85 88 78 84 Normal cells 93 96 92 95 Compound 24 AML 48 59 39 48 CML 51 69 46 51 CLL 48 67 39 48 Skin cancer 46 62 39 47 Breast cancer 54 77 47 58 Ovarian cancer 57 68 45 61 Brain tumor 66 74 54 69 Prostate cancer 61 75 51 62 Head and neck 64 76 57 68 squamous cell carcinomas Laryngeal cancer 65 75 55 66 Pancreatic cancer 55 68 49 62 Retinoblastoma 62 82 54 69 Children 67 75 57 68 hepatoblastoma Liver cancer 74 82 61 72 Malignant melanoma 81 88 76 86 Colorectal cancer 66 78 55 67 Colon 58 66 49 57 adenocarcinoma Glioma 69 78 60 74 Gastrointestinal 56 72 51 62 tumor Nasopharynx cancer 57 64 48 59 Brain glioma 52 65 42 53 Gastric cancer 51 66 39 48 Lung 68 78 55 64 adenocarcinoma Lung cancer 61 72 54 66 Normal cells 92 93 90 92 Compound 25 AML 35 47 26 44 CML 57 64 36 49 CLL 46 57 34 45 Skin cancer 55 66 43 58 Breast cancer 66 74 52 65 Ovarian cancer 64 76 55 67 Brain tumor 72 83 66 73 Prostate cancer 44 56 31 44 Head and neck 56 67 47 58 squamous cell carcinomas Laryngeal cancer 64 74 53 64 Pancreatic cancer 54 64 36 48 Retinoblastoma 55 64 34 54 Children 44 53 39 47 hepatoblastoma Liver cancer 52 65 46 54 Malignant melanoma 62 81 54 66 Colorectal cancer 62 76 55 66 Colon 42 55 35 49 adenocarcinoma Glioma 71 83 65 74 Gastrointestinal 54 63 44 52 tumor Nasopharynx cancer 45 54 37 48 Brain glioma 62 74 47 58 Gastric cancer 43 54 37 47 Lung 46 57 34 46 adenocarcinoma Lung cancer 42 54 29 37 Normal cells 89 93 88 91 Compound 26 AML 86 93 73 85 CML 88 92 76 79 CLL 84 93 74 85 Skin cancer 86 94 75 87 Breast cancer 85 89 74 86 Ovarian cancer 86 91 75 84 Brain tumor 84 89 73 85 Prostate cancer 86 92 77 89 Head and neck 84 91 78 88 squamous cell carcinomas Laryngeal cancer 80 88 75 82 Pancreatic cancer 86 90 77 86 Retinoblastoma 82 91 74 85 Children 85 93 79 86 hepatoblastoma Liver cancer 82 89 79 87 Malignant melanoma 82 88 76 86 Colorectal cancer 79 87 72 81 Colon 86 91 81 89 adenocarcinoma Glioma 87 94 76 87 Gastrointestinal 87 93 82 88 tumor Nasopharynx cancer 85 94 74 81 Brain glioma 84 88 76 85 Gastric cancer 83 88 77 84 Lung 85 91 82 87 adenocarcinoma Lung cancer 82 88 78 84 Normal cells 94 95 93 94 Compound 27 AML 87 90 77 86 CML 87 94 76 87 CLL 87 93 82 88 Skin cancer 85 94 74 81 Breast cancer 84 88 76 85 Ovarian cancer 83 88 77 84 Brain tumor 87 94 76 87 Prostate cancer 84 91 78 88 Head and neck 81 87 75 83 squamous cell carcinomas Laryngeal cancer 85 92 77 89 Pancreatic cancer 86 93 78 92 Retinoblastoma 85 94 80 86 Children 82 88 79 87 hepatoblastoma Liver cancer 86 90 77 86 Malignant melanoma 82 91 74 85 Colorectal cancer 85 93 79 86 Colon 82 89 78 87 adenocarcinoma Glioma 80 88 75 82 Gastrointestinal 86 90 77 86 tumor Nasopharynx cancer 82 91 74 85 Brain glioma 84 91 78 88 Gastric cancer 81 87 75 83 Lung 82 89 76 86 adenocarcinoma Lung cancer 79 88 72 81 Normal cells 88 91 81 89 Compound 28 AML 87 94 76 87 CML 85 92 77 89 CLL 82 91 73 87 Skin cancer 84 91 78 88 Breast cancer 81 87 75 83 Ovarian cancer 85 88 79 85 Brain tumor 82 91 73 87 Prostate cancer 84 91 78 88 Head and neck 81 87 75 83 squamous cell carcinomas Laryngeal cancer 85 92 77 89 Pancreatic cancer 86 93 78 92 Retinoblastoma 84 90 80 85 Children 85 92 77 89 hepatoblastoma Liver cancer 82 91 73 87 Malignant melanoma 84 91 78 88 Colorectal cancer 81 87 75 83 Colon 82 88 74 85 adenocarcinoma Glioma 85 93 79 86 Gastrointestinal 82 88 76 89 tumor Nasopharynx cancer 85 92 77 89 Brain glioma 82 89 76 86 Gastric cancer 79 88 72 81 Lung 88 91 81 89 adenocarcinoma Lung cancer 87 94 76 87 Normal cells 94 96 92 95 Compound 29 AML 84 91 78 88 CML 81 87 75 83 CLL 85 88 79 85 Skin cancer 82 91 73 87 Breast cancer 79 88 72 81 Ovarian cancer 88 91 81 89 Brain tumor 87 94 76 87 Prostate cancer 85 93 79 86 Head and neck 82 88 74 85 squamous cell carcinomas Laryngeal cancer 85 93 79 86 Pancreatic cancer 82 88 76 89 Retinoblastoma 85 92 77 89 Children 85 92 77 89 hepatoblastoma Liver cancer 85 92 77 89 Malignant melanoma 82 91 73 87 Colorectal cancer 84 91 78 88 Colon 81 87 75 83 adenocarcinoma Glioma 84 91 78 88 Gastrointestinal 81 87 75 83 tumor Nasopharynx cancer 85 88 79 85 Brain glioma 82 89 76 86 Gastric cancer 79 88 72 81 Lung 88 91 81 89 adenocarcinoma Lung cancer 87 94 76 87 Normal cells 93 96 92 95 Compound 35 AML 82 91 73 87 CML 84 91 78 88 CLL 81 87 75 83 Skin cancer 85 92 77 89 Breast cancer 86 93 78 92 Ovarian cancer 84 91 78 88 Brain tumor 81 87 75 83 Prostate cancer 85 88 79 85 Head and neck 82 91 73 87 squamous cell carcinomas Laryngeal cancer 82 89 76 86 Pancreatic cancer 79 88 72 81 Retinoblastoma 88 91 81 89 Children 87 94 76 87 hepatoblastoma Liver cancer 84 89 74 86 Malignant melanoma 87 91 75 84 Colorectal cancer 82 91 73 87 Colon 84 91 78 88 adenocarcinoma Glioma 81 87 75 83 Gastrointestinal 85 92 77 89 tumor Nasopharynx cancer 86 93 78 92 Brain glioma 84 92 78 87 Gastric cancer 85 92 77 89 Lung 82 91 73 87 adenocarcinoma Lung cancer 84 91 78 88 Normal cells 91 95 90 94 Compound 46 AML 82 88 74 85 CML 85 93 79 86 CLL 82 88 76 89 Skin cancer 85 92 77 89 Breast cancer 82 89 76 86 Ovarian cancer 79 88 72 81 Brain tumor 88 91 81 89 Prostate cancer 87 94 76 87 Head and neck 84 91 78 88 squamous cell carcinomas Laryngeal cancer 81 87 75 83 Pancreatic cancer 85 88 79 85 Retinoblastoma 82 91 73 87 Children 84 91 78 88 hepatoblastoma Liver cancer 81 87 75 83 Malignant melanoma 85 92 77 89 Colorectal cancer 86 93 78 92 Colon 84 89 74 86 adenocarcinoma Glioma 87 91 75 84 Gastrointestinal 82 89 76 86 tumor Nasopharynx cancer 79 88 72 81 Brain glioma 88 91 81 89 Gastric cancer 87 94 76 87 Lung 85 93 79 86 adenocarcinoma Lung cancer 82 88 76 89 Normal cells 94 95 92 94 Compound 47 AML 79 88 73 82 CML 85 92 77 89 CLL 82 91 73 87 Skin cancer 84 91 78 88 Breast cancer 82 91 73 87 Ovarian cancer 84 91 78 88 Brain tumor 81 87 75 83 Prostate cancer 85 92 77 89 Head and neck 86 93 78 92 squamous cell carcinomas Laryngeal cancer 85 93 79 86 Pancreatic cancer 84 91 78 88 Retinoblastoma 81 87 75 83 Children 85 88 79 85 hepatoblastoma Liver cancer 82 91 73 87 Malignant melanoma 82 89 76 86 Colorectal cancer 79 88 72 81 Colon 88 91 81 89 adenocarcinoma Glioma 87 94 76 87 Gastrointestinal 78 89 74 81 tumor Nasopharynx cancer 82 88 74 85 Brain glioma 85 93 79 86 Gastric cancer 82 88 76 89 Lung 85 92 77 89 adenocarcinoma Lung cancer 85 93 79 86 Normal cells 93 95 92 94 Compound 48 AML 47 59 38 48 CML 51 69 46 51 CLL 46 67 38 48 Skin cancer 46 62 39 47 Breast cancer 54 76 47 58 Ovarian cancer 56 68 45 61 Brain tumor 66 78 53 69 Prostate cancer 62 75 51 62 Head and neck 64 73 58 68 squamous cell carcinomas Laryngeal cancer 63 76 55 66 Pancreatic cancer 55 68 49 62 Retinoblastoma 62 82 54 69 Children 68 75 56 68 hepatoblastoma Liver cancer 74 82 61 73 Malignant melanoma 82 88 76 86 Colorectal cancer 66 79 55 67 Colon 58 66 49 56 adenocarcinoma Glioma 69 78 60 74 Gastrointestinal 57 73 52 62 tumor Nasopharynx cancer 57 64 48 59 Brain glioma 52 66 43 54 Gastric cancer 51 66 39 48 Lung 67 77 55 64 adenocarcinoma Lung cancer 61 72 54 67 Normal cells 91 92 89 91 Compound 49 AML 85 92 77 89 CML 87 90 76 86 CLL 82 91 74 85 Skin cancer 85 93 79 86 Breast cancer 82 89 79 87 Ovarian cancer 86 93 76 88 Brain tumor 83 88 79 87 Prostate cancer 85 92 77 89 Head and neck 82 91 73 87 squamous cell carcinomas Laryngeal cancer 84 91 78 88 Pancreatic cancer 81 87 75 83 Retinoblastoma 85 92 77 89 Children 86 93 78 92 hepatoblastoma Liver cancer 85 93 79 86 Malignant melanoma 82 88 79 87 Colorectal cancer 82 88 74 85 Colon 85 93 79 86 adenocarcinoma Glioma 82 88 76 89 Gastrointestinal 85 92 77 89 tumor Nasopharynx cancer 84 93 77 86 Brain glioma 83 88 79 87 Gastric cancer 85 92 77 89 Lung 84 91 78 88 adenocarcinoma Lung cancer 79 88 73 82 Normal cells 94 96 92 95 Compound 50 AML 45 57 36 47 CML 57 64 46 58 CLL 47 58 36 47 Skin cancer 57 66 43 58 Breast cancer 64 75 52 65 Ovarian cancer 62 77 55 67 Brain tumor 62 72 54 63 Prostate cancer 54 66 41 54 Head and neck 56 67 47 58 squamous cell carcinomas Laryngeal cancer 64 75 53 64 Pancreatic cancer 53 64 43 49 Retinoblastoma 54 65 44 53 Children 42 55 34 47 hepatoblastoma Liver cancer 53 66 46 54 Malignant melanoma 64 82 54 66 Colorectal cancer 64 76 55 66 Colon 43 55 35 49 adenocarcinoma Glioma 62 74 45 56 Gastrointestinal 55 64 44 53 tumor Nasopharynx cancer 44 54 37 48 Brain glioma 63 74 47 58 Gastric cancer 45 54 37 48 Lung 46 57 36 47 adenocarcinoma Lung cancer 43 54 33 47 Normal cells 90 92 89 91

Embodiment 4 Injection

Respectively dissolve Compounds 1-50 prepared in Embodiment 1 with a few amount of DMSO and then add water for injection as normal, filter precisely, charge and seal before sterilize them to prepare into injection.

Embodiment 5 Tablet

Add excipient with a ratio of 5:1 by weight between Compounds 1-50 prepared in Embodiment 1 and excipient. Pellitize and tablet it to make tablet.

Embodiment 6 Capsule

Add excipient with a ratio of 5:1 by weight between Compounds 1-50 prepared in Embodiment 1 and excipient. Pellitize and tablet it to make capsule.

The compounds, uses and methods according to the present invention have been described in the specific embodiments as above. Those skilled in the art can refer to the contents of the present invention to appropriately modify the factors such as raw materials or process conditions to realize other corresponding purposes. Nevertheless, no related changes shall break away from the contents of the present invention and all the similar substitutions and changes are obvious to those skilled in the art and shall be deemed within the scope of the present invention. 

What is claimed is:
 1. Uses of the compounds of Formula (I) in preparing drugs.

where: R_(1 and) R₂ form double bond together or R₁ is hydrogen or deuterium, R₂ is

and the pharmaceutically acceptable salts formed by it and inorganic acid or organic acid including the quaternary ammonium salts formed with R₅Z, where R₃ and R₄ can be the same or different selected from hydrogen, alkyl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic, trifluoromethyl, polyfluoroalkyl, nitrile group, cyanomethyl, acyl, carbamoyl, sulfonyl, sulfonamide or aryloxyalkyl; R₃, R₄ and N atom form cyclic structure which is preferably 3-member to 9-member ring, where one or more positions on the ring structure can be replaced by the substituent group including hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl or heterocyclic; Z is fluorine, chlorine, bromine, iodine, toluene-p-sulfonate group, mesylate group, benzenesulfonate group or trifluoromethanesulfonate group; R₅ is alkayl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, heterocyclic, aryl-substituting alkyl, arylalkenyl, arylalkynyl, cyano methyl, alkoxy-substituting alkyl or aryloxy substituting alkyl. Inorganic or organic acid can be hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, boric acid, selenious acid, phosphomolybdic acid, phosphorous acid, sulfurous acid, citric acid, maleic acid, D-malic acid, L-malic acid, DL-malic acid, L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, methanesulfonic acid, acid, oleic acid, lauric acid, p-toluenesulfonic, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, phthalic acid, tartaric acid, malonic acid, succinic acid, fumaric acid, glycolic acid, a thiol acid, glycine, sarcosine, sulfonic acid, nicotinic acid, picoline acid, isonicotinic, dichloroacetic acid, benzoic acid or substituted benzoic acid. Or R₂ is

where X thereof is O or S, R₆ is hydrogen, alkyl, cycloalkyl, hydroxy-substituting alkyl, alkenyl, alkynyl, aryl, alkylaryl, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic, trifluoromethyl, polyfluoroalkyl, nitrile group, cyanomethyl, acyl, carbamoyl, sulfonyl, sulfonamide or aryloxyalkyl. If there is no the bond - - - between R₇ and R₈, R₇ and R₈ will form double bond together or R₇ is methyl, R₈ is hydroxyl or OCOR₉ where R₉ thereof is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic. If the bond - - - between R₇ and R₈ is single bond, R₇═R=methylene. R₁₀ is hydrogen or R₁₀ and R₈ form single bond. R₁₁ is hydrogen or R₁₁ and R₁₃ form single bond or epoxy bond. If there is no bond - - - between R₁₂ and R₁₃, R₁₂ and R₁₃ will form double bond together or R₁₂ is hydroxyl or R₁₄, where R₁₄ thereof is alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, R₁₃ is methyl. If the bond - - - between R₁₂ and R₁₃ is single bond, R₁₂═R₁₃=methylene.
 2. According to claim 1, the structural formula (I) is preferably:


3. The uses of the compound(s) according to any claim of claim 1 to claim 2 in preparing drugs to treat rheumatoid arthritis.
 4. The uses of the compound(s) according to any claim of claim 1 to claim 2 in preparing adjuvant drugs to treat rheumatoid arthritis.
 5. The uses of the compound(s) according to any claim of claim 1 to claim 2 in preparing drugs to treat cancers through inhibiting cancer stem cells, where the cancers thereof are preferably acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, skin cancer, breast cancer, ovarian cancer, brain tumor, prostate cancer, head and neck squamous cell carcinoma, laryngeal cancer, pancreatic cancer, retinoblastoma, children hepatoblastoma, liver cancer, malignant melanoma, colorectal cancer, colon cancer, glioma, gastrointestinal tumor, nasopharyngeal carcinoma, brain glioma, gastric cancer, lung cancer and lung cancer.
 6. The uses of any compound according to claim 1 to claim 2 in preparing the adjuvant drugs to treat cancers through inhibiting cancer stem cells, where the cancers thereof are preferably acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, skin cancer, breast cancer, ovarian cancer, brain tumor, prostate cancer, head and neck squamous cell carcinoma, laryngeal cancer, pancreatic cancer, retinoblastoma, children hepatoblastoma, liver cancer, malignant melanoma, colorectal cancer, colon cancer, glioma, gastrointestinal tumor, nasopharyngeal carcinoma, brain glioma, gastric cancer, lung cancer and lung cancer.
 7. A pharmaceutical composition to treat rheumatoid arthritis, where said pharmaceutical composition comprises at least one compound according to any claim from claim 1 or claim 2 as the active component and a pharmaceutically acceptable carrier or other compound(s) to treat rheumatoid arthritis.
 8. A pharmaceutical composition to treat cancers through inhibiting cancer stem cells, where said pharmaceutical composition comprises at least one compound according to any claim from claim 1 to claim 2 as the active and a pharmaceutically acceptable carrier or other compound(s) to treat cancers through inhibiting cancer stem cells component and the cancers thereof are preferably acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, skin cancer, breast cancer, ovarian cancer, brain tumor, prostate cancer, head and neck squamous cell carcinoma, laryngeal cancer, pancreatic cancer, retinoblastoma, children hepatoblastoma, liver cancer, malignant melanoma, colorectal cancer, colon cancer, glioma, gastrointestinal tumor, nasopharyngeal carcinoma, brain glioma, gastric cancer, lung cancer and lung cancer. 